{
  "schema_version": "1.3.1",
  "doc": {
    "doc_id": "a41ed85d77987b37c64fa5953a17281b",
    "title": "US Biopharmaceuticals",
    "source_uri": "2025-08-29/GLP1 tracker Wegovy flattens Zepbound still below pre-CVS change levels WE 22nd AugustGLP1 tracker Wegovy flattens Zepbo_2025-08-29",
    "language": "en",
    "timestamps": {
      "ingested_at": "2025-10-26T23:51:44.133617",
      "extracted_at": "2025-10-26T23:51:44.133627"
    },
    "extraction_run": {
      "vision_model": "deepseek-ai/DeepSeek-OCR",
      "synthesis_model": "rule-based-engine",
      "pipeline_steps": [
        "ocr",
        "rule_extraction",
        "figure_vision"
      ],
      "processing_metadata": {
        "pages_processed": 20,
        "successful_pages": 20,
        "date": "2025-08-29",
        "publication": "2025-08-29",
        "authors": [],
        "markdown_cleaning": {
          "removed_sections": 1,
          "removed_paragraphs": 5,
          "reduction_ratio": 0.032221765767053046
        },
        "input_relative_path": "2025-08-29"
      }
    }
  },
  "passages": [
    {
      "passage_id": "6edce5e754fd8820",
      "text": "Weekly GLP- 1 scripts are still hovering around the 2 million mark, up by a small amount (+0.6%) on last week. Wegovy scripts continue to flatten off, whilst Mounjaro climbs higher and Zepbound still tracks below the pre- 7/1 (CVS Wegovy formulary change) level. Ozempic is now in YoY decline (- 0.5%, 4 wk avg).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "ba03732be07fbbc8",
      "text": "No IQVIA data irregularities to report this week, although our 4- week average growth numbers still include the lower Zepbound vials number from the week ending (WE) 8th August under- reporting, so this should be taken into account.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7d16e2409f4018b0",
      "text": "Total scripts: Total weekly scripts for the week ending 22nd August were 2.06M, up 12k (+0.61%) from last week. The 4- week sequential growth rate for sema- ttrz was +0.9%, compared to 1.1% last week. The 4- week YoY growth for sema- ttrz was 42.9%, slightly down from 45.5% last week (note that recent reporting issues may understate actual growth). The company market share split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "7cfd273f50ec8801",
      "text": "Zepbound: Weekly market share for Zepbound stands at 21.9%, stable on last week. Year on year growth (based on 4wk rolling avg) has dropped, partially owing to the underreporting during the WE 8th Aug, and currently sits at 179%. Previously this had been over 200% in May- July. Assuming the \\(\\sim 120k\\) vials been included in WE 8th Aug, growth would still be 200%. However, as expected, Zepbound's exceptional growth cannot continue forever, and is mean- reverting too (Exhibit 17).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f612f5e93f16368b",
      "text": "Mounjaro: is stably ticking along at around 62% (4- week YoY) growth, down slightly from 70%, a level at which it has been hovering at since the end of May. However, looking at Exhibit 1 and Exhibit 2, Mounjaro looks to be accelerating whilst the other products slightly stagnate. As a result, its market share rose to 33.2% (+0.3%).",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "f2212f5f7fc7afd6",
      "text": "Semaglutide: Ozempic (T2D) has now recorded a second consecutive week of year- on- year decline, with a 4- week average of - 0.5%. Overall, semaglutide (combining both Ozempic and Wegovy) posted 9.3% YoY growth, a slight decrease from 9.8% last week. Both brands are driving this slowdown, Wegovy's YoY growth moderated to 36.8%, down from 38.0% last week, though this remains above the 23% low seen at the end of June.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1e50533d271c96a5",
      "text": "Note: We'd caution interpretation of 4 weekly average values given the misreporting for Zepbound in the week before last.",
      "page": 0,
      "section": null
    },
    {
      "passage_id": "1246abab66184d6d",
      "text": "Ticker28 Aug2025TTMAdjusted EPSAdjusted P/E (x)RatingCurClosingPricePriceTargetRel. Perf.Cur2024A2025E2026E2024A2025E2026ELLYOUSD731.961,100.00(38.4)%USD12.9922.8430.1556.332.024.3SPX6,501.86",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "3b25fb5309f11955",
      "text": "O - Outperform, M - Market-Perform, U - Underperform, NR - Not Rated, CS - Coverage Suspended",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "0f55d27f39be3d49",
      "text": "Source: Bloomberg, Bernstein estimates and analysis.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "632fc9c58b5aaa65",
      "text": "We rate LLY Outperform with a price target of &#36;1,100.",
      "page": 1,
      "section": null
    },
    {
      "passage_id": "c0b41b45d045c39c",
      "text": "TRX demonstrates total scripts, whereas NRX demonstrates all new prescriptions (regardless of whether they are for new patients, or for renewals for current patients).",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "e5c0398839b2d186",
      "text": "In the graphs below, we can see Zepbound and Mounjaf holding strong, but a clear uptick in Wegovy associated with the CVS Caremark formulary.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dbdb3024fb2a8e7c",
      "text": "EXHIBIT 1: GLP1 Weekly TRx data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5b37b67bcd7b5d52",
      "text": "Source: IQVIA, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "adad0f11e115ab47",
      "text": "EXHIBIT 2: GLP1 Weekly NRx data",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "dac7261d245af04b",
      "text": "Source: IQVIA, Bernstein analysis",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "f8b2ba080dabcc2f",
      "text": "NBRx data - new to brand demonstrates with greater fidelity what we are seeing from the CVS Caremark formulary change. Overall Zepbound NBRx numbers are higher than what is evident for Wegovy, despite a \\(+80k\\) increase in NBRx for Wegovy driven by switches since the CVS Caremark preferred status came into effect.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "5b2afa324c06eff0",
      "text": "Note, the new to brand weekly data is released by IQVIA at a lag to the rest of the weekly data. Represented below is August 1st data, please reach- out if you'd like updated graphs before our next tracker when the data is released next week. We expect further stabilization / growth in the NBRx data for Zepbound.",
      "page": 2,
      "section": null
    },
    {
      "passage_id": "cfea6aa268df8fc5",
      "text": "EXHIBIT 3: New patient starts (NBRx) by product",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "1dc38b409e7193c1",
      "text": "Data from week ending 15-Aug Source:IQVIA,Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "519411a636bd7afa",
      "text": "EXHIBIT 4: NBRx - Broken out by pens and vials for Zepbound (vs Wegovy)",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "019c7dc06ff20519",
      "text": "Data from week ending 15-Aug Source:IQVIA,Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "9eefa2486cb34650",
      "text": "EXHIBIT 5: The percentage of NBRx captured by Zepbound took a hit following Wegovy's CV5 preferred status, but has since rebounded",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "a4363c4cd4b71d20",
      "text": "Data from week ending 15-Aug Source:IQVIA,Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "d37920e09e5a7a7a",
      "text": "EXHIBIT 6: % of New Patient Starts coming from Switches",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "e294accf28406769",
      "text": "Data from week ending 15-Aug Source:IQVIA,Bernstein analysis",
      "page": 3,
      "section": null
    },
    {
      "passage_id": "bc169ff45c567000",
      "text": "EXHIBIT 7: Weekly switches show a slowing proportion of patients moving to Wegovy now",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "103691f95ad7f7b5",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "cc81a40b8e83019f",
      "text": "EXHIBIT 8: Wegovy switches have come back down following the mass CVS switching event on 7/1",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "a9433d1ae153d9bc",
      "text": "Source:IQVIA,Bernstein Analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "569df59956600049",
      "text": "EXHIBIT 9: Semaglutide vs Tirzepatide - 4 weekly average TRx share",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "2daf55ad4d61a8f4",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "91eca70859098e1c",
      "text": "EXHIBIT 10: 4 weekly average TRx share by Brand",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "8e7cfaa6af3ed2b4",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 4,
      "section": null
    },
    {
      "passage_id": "1d8156740e45bfe7",
      "text": "EXHIBIT 11: TRx 4 week growth rate",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "3aa5f865c669f51b",
      "text": "TRx addsMay 09-May 30Jun 06-Jun 27Jul 04-Jul 25Aug 01-Aug 22Mounjaro2,215,8302,339,6642,404,0162,478,177vs prior 4 weeks (abs)123,83464,35274,161vs prior 4 weeks (%)5.6%2.8%3.1%Zepbound1,433,5351,739,0511,629,5781,553,164vs prior 4 weeks (abs)305,516109,47376,414vs prior 4 weeks (%)21.3%-6.3%-4.7%M+Z together3,649,3654,078,7154,033,5944,031,341vs prior 4 weeks (abs)429,35045,1212,253vs prior 4 weeks (%)11.8%-1.1%-0.1%Other LLY (trulicity)640,469642,198631,515623,261vs prior 4 weeks (abs)1,72910,6838,254vs prior 4 weeks (%)0.3%-1.7%-1.3%Ozempic2,342,8462,381,5262,328,5552,305,275vs prior 4 weeks (abs)38,68052,97123,280vs prior 4 weeks (%)1.7%-2.2%-1.0%Wegovy858,206924,2221,035,0081,126,134vs prior 4 weeks (abs)66,016110,78691,126vs prior 4 weeks (%)7.7%12.0%8.8%O+W together3,201,0523,305,7483,363,5633,431,409vs prior 4 weeks (abs)104,69657,81567,846vs prior 4 weeks (%)3.3%1.7%2.0%Other Novo (Saxenda/Victoza)10,8149,6658,90010,857vs prior 4 weeks (abs)1,1497651,957vs prior 4 weeks (%)-10.6%-7.9%22.0%M+Z+O+W6,850,4177,384,4637,397,1577,462,750vs prior 4 weeks (abs)534,04612,69465,593vs prior 4 weeks (%)7.8%0.2%0.9%",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "00da789e04988cbb",
      "text": "Source: IQVIA, Bernstein analysis",
      "page": 5,
      "section": null
    },
    {
      "passage_id": "1e48ab64ac1d47b4",
      "text": "EXHIBIT 12: Total GLP-1 Weekly TRx",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "f567b06c7f58016d",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "734a999904374347",
      "text": "EXHIBIT 13: Total GLP-1 Weekly NRx",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "41a02145c2f29502",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "c5e5c90fb34b8c68",
      "text": "EXHIBIT 14: Market share evolution (TRx)",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "f79ff5a5d1ac1c0d",
      "text": "Market share - TRxCurrent Week: 22-Aug-25This week (scripts)This week %Past 4 weeks %Past 12 weeks %MounjaroLLY630,23130.6%30.6%29.9%ZepboundLLY415,85820.2%19.2%20.4%TrulicityLLY155,5147.6%7.7%7.8%TotalLLY1,201,60358.3%57.5%58.1%OzempicNOVO574,40827.9%28.5%29.0%WegovyNOVO280,54413.6%13.9%12.8%Victoza/SaxendaNOVO3,1920.2%0.1%0.1%TotalNOVO858,14441.7%42.5%41.9%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "4c825fd619fa48b4",
      "text": "Market share - TRx just sema/tirzCurrent Week: 22-Aug-25This week (scripts)This week %Past 4 weeks %Past 12 weeks %MounjaroLLY630,23133.2%33.2%32.5%ZepboundLLY415,85821.9%20.8%22.1%M&amp;amp;ZLLY1,046,08955.0%54.0%54.6%OzempicNOVO574,40830.2%30.9%31.5%WegovyNOVO280,54414.8%15.1%13.9%O&amp;amp;WNOVO854,95245.0%46.0%45.4%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "1d7ae37ad8358f77",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "0d16c863e11efc80",
      "text": "EXHIBIT 15: Last week's market share evolution",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "9ec1b7e33f88281c",
      "text": "Market share - TRxCurrent Week: 15-Aug-25This week (scripts)This week %Past 4 weeks %Past 12 weeks %MounjaroLLY621,43130.4%30.4%29.9%ZepboundLLY414,37620.2%19.4%20.3%TrulicityLLY154,0047.5%7.7%7.9%TotalLLY1,189,81158.1%57.6%58.1%OzempicNOVO574,60428.1%28.4%29.2%WegovyNOVO280,46913.7%13.9%12.7%Victoza/SaxendaNOVO2,4030.1%0.1%0.1%TotalNOVO857,47641.9%42.4%41.9%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "ccd0a923e5c4fed0",
      "text": "Market share - TRx just sema/tirzCurrent Week: 15-Aug-25This week (scripts)This week %Past 4 weeks %Past 12 weeks %MounjaroLLY621,43132.9%33.0%32.4%ZepboundLLY414,37621.9%21.1%22.1%M&amp;amp;ZLLY1,035,80754.8%54.1%54.5%OzempicNOVO574,60430.4%30.9%31.7%WegovyNOVO280,46914.8%15.0%13.8%O&amp;amp;WNOVO855,07345.2%45.9%45.5%",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "67cd30105e3a7ad4",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 6,
      "section": null
    },
    {
      "passage_id": "e0d6f3971ce87fbf",
      "text": "EXHIBIT 16: Zebound vs Wegovy (% share, based on 4wk TRx averages)",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "0b6f0376a440080b",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 7,
      "section": null
    },
    {
      "passage_id": "cdfb4d8975ca18e4",
      "text": "EXHIBIT 17: Rolling 4-weekly year-on-year volume growth for GLP-1s",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "5742ca9e886cf8f6",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "e07574c64d7caee3",
      "text": "EXHIBIT 18: TRx 4-week growth rate vs prior year",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "4d5c38b1a10c1c3b",
      "text": "TRx adds2023/20242024/2025May 10-May 31Jun 07-Jun 28Jul 05-Jul 26Aug 02-Aug 23May 09-May 30Jun 06-Jun 27Jul 04-Jul 25Aug 01-Aug 22Mounjaro vs PY (abs)1,324,0951,381,3191,406,5421,525,8022,215,8302,339,6642,404,0162,478,177vs PY (%)891,735958,345997,474952,375Zepbound vs PY (abs)386,758465,522502,934557,70167.3%69.4%70.9%62.4%vs PY (%)1,433,5351,739,0511,629,5781,553,164M+Z together vs PY (abs)1,710,8531,846,8411,909,4762,083,5031,046,7771,273,5291,126,644995,463vs PY (%)270.7%273.6%224.0%178.5%M+Z together vs PY (abs)1,710,8531,846,8411,909,4762,083,5033,649,3654,078,7154,033,5944,031,341vs PY (%)1,938,5122,231,8742,124,1181,947,838Other LLY (triclity)662,854699,438727,827723,660640,469642,198631,515623,261vs PY (abs)22,38557,24096,312100,399vs PY (%)-3.4%-8.2%-13.2%-13.9%Ozempic vs PY (abs)2,211,5202,331,5562,280,9052,316,9812,342,8462,381,5262,328,5552,305,275vs PY (%)131,32649,97047,65011,706Wegovy vs PY (abs)668,430750,168769,822823,3505.9%2.1%2.1%-0.5%vs PY (%)858,206924,2221,035,0081,126,134O+W together vs PY (abs)2,879,9503,081,7243,050,7273,140,331189,776174,054265,186302,784vs PY (%)28.4%23.2%34.4%36.8%O+W together vs PY (abs)2,879,9503,081,7243,050,7273,140,3313,201,0523,305,7483,363,5633,431,409vs PY (%)321,102224,024312,836291,078Other Novo (Saxenda/Victoza) vs PY (abs)98,43979,79453,21452,45411.1%7.3%10.3%9.3%vs PY (%)10,8149,6658,90010,857M+Z+O+W vs PY (abs)4,590,8034,928,5654,960,2035,223,834-87,62570,12944,31441,597vs PY (%)-89.0%-87.9%-83.3%-79.3%M+Z+O+W vs PY (abs)4,590,8034,928,5654,960,2035,223,8346,850,4177,384,4637,397,1577,462,750vs PY (%)2,259,6142,455,8982,436,9542,238,91649.2%49.8%49.1%42.9%",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "61d27d1280e363d8",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 8,
      "section": null
    },
    {
      "passage_id": "66792cd955c126b1",
      "text": "EXHIBIT 19: Mounjaro TRx by dose",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "9541ac7a63f62b1e",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8499f3cd1cc58d29",
      "text": "EXHIBIT 20: Zepbound TRx by dose",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "b832db4d92c74121",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "20c15503d5a647a9",
      "text": "EXHIBIT 21: Ozempic TRx by dose",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "dfae8101bde70e1d",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 9,
      "section": null
    },
    {
      "passage_id": "8c2c4fd511171c09",
      "text": "EXHIBIT 22: Wegovy TRx by dose",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "fe2f98c999a2995c",
      "text": "Source:IQVIA,Bernstein analysis",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "e7ced53c0064db8d",
      "text": "Prior GLP1 tracker notes:",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "c67723066ab59505",
      "text": "Prior GLP1 tracker notes:- 22 Aug 2025 - GLP1 tracker: Semaglutide switches slow (W/E 15th August)- 15 Aug 2025 - GLP1 tracker: Wegovy rounding out? And Zepbound reporting issues (W/E 8th August)- 08 Aug 2025 - GLP1 tracker: Easing of Sema switches continue (W/E 1st August)- 01 Aug 2025 - GLP1 tracker: Rate of Wegovy switches subsiding & Zepbound share beginning to rebound (W/E 25th July)- 25 Jul 2025 - GLP1 tracker: Wegovy continues to gain off CVS- switches (W/E 18th July)- 11 July 2025 - GLP1 tracker: Is Mounjaro the real beneficiary of Wegovy's CVS preferred status? (W/E 4th July)- 04 July 2025 - GLP1 tracker: Lilly gains before potentially choppy scripts ahead (W/E 27th June)- 27 Jun 2025 - GLP1 tracker: Week on week Wegovy up & Zepbound down - (W/E 20th June)- 23 June 2025 - GLP1 tracker: Not a Novo rebound just yet (W/E 13th June)- 13 June 2025 - GLP1 tracker: Zepbound continues to propel Lilly (W/E 6th June)- 6 June 2025 - GLP1 tracker: Lighter scripts for the market, but still growth YoY (W/E 30th May)- 30 May 2025 - GLP1 tracker: Zepbound continues to rocket, some volumes still to be validated by IQVIA (W/E 23rd May)- 23 May 2025 - GLP1 tracker: LLY growth continues, despite Zepbound data issues continuing (W/E 16th May)- 19 May 2025 - GLP1 tracker: Zepbound TRx drops (underreporting via IQVIA) (W/E 9th May)- 13 May 2025 - GLP1 tracker: Total scripts jump, but Lilly more so than Novo (W/E 2nd May)- 05 May 2025 - GLP1 tracker: Softer week for total scripts, but Lilly still gains share (W/E 25th April)- 28 Apr 2025 - GLP1 tracker: LLY share ticks upward more marginally, growth remains strong (W/E 18th April)- 21 Apr 2025 - GLP1 tracker: The story repeats - LLY keeps taking share (52%), growing faster than supply guidance & faster than NOVO (W/E 11th April)- 14 Apr 2025 - GLP1 tracker: LLY keeps taking share, growing faster than supply guidance & faster than NOVO (W/E 4th April)",
      "page": 10,
      "section": null
    },
    {
      "passage_id": "f749ab1b81310e7c",
      "text": "- 4 Apr 2025 - GLP1 tracker: Medicare exclusion quicktake; Script growth is back, LLY driving growth, NovoCare likely absent [W/E 28th March]",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "9995c48019df6f78",
      "text": "- 31 Mar 2025 - GLP1 tracker: Continued superiority demonstrated in scripts for tirzepatide, waiting to see impact of Novo cash-pay [W/E 21st March]",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f8ca9bef00b266e5",
      "text": "- 24 Mar 2025 - GLP1 tracker: Recent trends continue, although M drives LLY's market share expansion (rather than Z) [W/E 14th March]",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "c97a93ee5269fb5f",
      "text": "- 17 Mar 2025 - GLP1 Tracker: LLY takes majority share & anti-cancer potential for retatrutide [W/E 7th March]",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "b42b172dae7e53f6",
      "text": "- 10 Mar 2025 - GLP1 Tracker: Lilly continues to outgrow Novo with market share now rounding to 50% [W/E 28th Feb]",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "c8b19147afee27f3",
      "text": "- 3 Mar 2025 - GLP1 Tracker: Lilly continues to outgrow Novo with market share stretching towards equal (49.1%) [W/E 21st Feb]",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "e953270401c50cec",
      "text": "- 25 Feb 2025 - GLP1 tracker: Zepbound price-drop announced, uptick with LillyDirect visibility, not yet seeing more starter doses on sema",
      "page": 11,
      "section": null
    },
    {
      "passage_id": "f04516dc3fda84cf",
      "text": "References to \"Bernstein\" or the \"Firm\" in these disclosures relate to the following entities: Bernstein Institutional Services LLC (April 1, 2024 onwards), Sanford C. Bernstein & Co., LLC (pre April 1, 2024), Bernstein Autonomous LLP, BSG France S.A. (April 1, 2024 onwards), Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH00006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社).",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "8bc352ecdb4945f3",
      "text": "On April 1, 2024, Société Générale (SG) and AllianceBernstein, LP. (AB) completed a transaction that created a new joint venture in which their respective cash equities and research businesses operate in a new business combination. Although their respective ownership percentages in the joint venture differ between North America and the rest of the world, the creation, production and publication of research is handled collaboratively on a global basis across the two research brands, \"Bernstein\" and \"Autonomous\". Unless specifically noted otherwise, for purposes of these disclosures, references to Bernstein's \"affiliates\" relate to both SG and AB and their respective affiliates.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "b5d4805f5a36110d",
      "text": "We arrive at our valuation using a blend of DCF (7.9% WACC, 6% FCFF CAGR to '43 and 3% TV GR) and multiples approach - with valuation more heavily weighted toward the DCF. Our \\(\\) 1100\\(valuation implies a FY26 PE multiple well above pharma peers, although within the range of trading over the TTM.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "412db3ed7081c6bc",
      "text": "Downside: Pressures on obesity TAM are more substantial than we estimate (demand, regulatory, pricing, competitive, compounding)",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "747470d18c308843",
      "text": "Downside: Manufacturing expansion stalls, limiting LLY obesity expansion",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "07d0e5a22c1251c5",
      "text": "Downside: Excess value destruction through high- risk M&A / R&D advancement",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "a666dd63a8e2dd27",
      "text": "The Bernstein brand rates stocks based on forecasts of relative performance for the next 12 months versus the S&P 500 for stocks listed on the U.S. and Canadian exchanges, versus the Bloomberg Europe Developed Markets Large and Mid Cap Price Return Index (EDM) for stocks listed on the European exchanges and emerging markets exchanges outside of the Asia Pacific region, versus the Bloomberg Japan Large and Mid Cap Price Return Index USD (JP) for stocks listed on the Japanese exchanges, and versus the Bloomberg Asia ex- Japan Large and Mid Cap Price Return Index (ASIAX) for stocks listed on the Asian (ex- Japan) exchanges - unless otherwise specified.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "7dea5ce983a9a028",
      "text": "The Bernstein brand has three categories of ratings:",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "a3a52471b3345f03",
      "text": "Outperform: Stock will outpace the market index by more than 15 pp Market- Perform: Stock will perform in line with the market index to within \\(+ / - 15\\) pp Underperform: Stock will trail the performance of the market index by more than 15 pp",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "80cc8e71bfa805e9",
      "text": "Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "bacf2922946b74fc",
      "text": "Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.",
      "page": 12,
      "section": null
    },
    {
      "passage_id": "054f8d7721b9600f",
      "text": "Not Covered (NC) denotes companies that are not under coverage.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "b0a94c10c4a5e14b",
      "text": "The Autonomous brand rates stocks as indicated below. As our benchmarks we use the Bloomberg Europe 500 Banks And Financial Services Index (BEBANKS) and Bloomberg Europe Dev Mkt Financials Large and Mid Cap Price Ret Index EUR (EDMFI) index for developed European banks and Payments, the Bloomberg Europe 500 Insurance Index (BEINSUR) for European insurers, the S&P 500 and S&P Financials for US banks and Payments coverage, S5LIFE for US Insurance, the S&P Insurance Select Industry (SPSIINS) for US Non- Life Insurers coverage, and the Bloomberg Emerging Markets Financials Large, Mid and Small Cap Price Return Index (EMLSF) for emerging market banks and insurers and Payments. Ratings are stated relative to the sector (not the market).",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "21f44e3144fb3f1d",
      "text": "The Autonomous brand has three categories of ratings:",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "530057c92853cd3d",
      "text": "Outperform (OP): Stock will outpace the relevant index by more than 10 pp- Neutral (N): Stock will perform in line with the market index to within \\(+ / - 10\\) pp- Underperform (UP): Stock will trail the performance of the relevant index by more than 10 pp",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "056b42429f44845b",
      "text": "Coverage Suspended: Coverage of a company under the Bernstein research brand has been suspended. Ratings and price targets are suspended temporarily, are no longer current, and should therefore not be relied upon. Not Rated: A rating assigned when the stock cannot be accurately valued, or the performance of the company accurately predicted, at the present time. The covering analyst may continue to publish research reports on the company to update investors on events and developments.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "cd7843acb618963f",
      "text": "Those denoted as 'Feature' (e.g., Feature Outperform FOP, Feature Under Outperform FUP) are our core ideas. Not Covered (NC) denotes companies that are not under coverage.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "dcaf809db6cfce58",
      "text": "For both brands, recommendations are based on a 12- month time horizon.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "0ef67c71d9bf2810",
      "text": "DISTRIBUTION OF EQUITY RATINGS/INVESTMENT BANKING SERVICES",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "e8b9496a9ce85c83",
      "text": "RatingMarket Abuse Regulation (MAR) and FINRA Rule 2241 classificationCountPercentCount*Percent*OutperformBUY58551.27%11018.80%Market-Perform (Bernstein Brand)HOLD40735.67%7618.67%Neutral (Autonomous Brand)UnderperformSELL14913.06%2013.42%",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "7df9a019e3d0ca94",
      "text": "\\* These figures represent the number and percentage of companies in each category to whom affiliates of Bernstein and Autonomous provided investment banking services. As of June 30, 2025. All figures are updated quarterly.",
      "page": 13,
      "section": null
    },
    {
      "passage_id": "5bf281ee3d5245b0",
      "text": "Bernstein Autonomous LLP or BSG France SA, beneficially, has either a net long or short position of \\(0.5\\%\\) or more of the total issued share capital of a class of common equity securities of the following MiFID eligible securities: Eli Lilly & Co.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "9dbb67f2070726b1",
      "text": "Certain affiliates of Bernstein act as market maker or liquidity provider in the equities securities of: Eli Lilly & Co.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "2efeb0f4b7231c56",
      "text": "Certain affiliates of Bernstein act as market maker or liquidity provider in the debt securities of: Eli Lilly & Co.",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "b457a5f09e125918",
      "text": "The legal entity(ies) employing the analyst(s) listed in this report, and their location, can be determined by the country code of their phone number, as follows:",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "269ad0fe8b13411e",
      "text": "+1 Bernstein Institutional Services LLC; New York, New York, USA+44 Bernstein Autonomous LLP; London UK+33 BSG France S.A.; Paris, France+34 BSG France S.A.; Madrid, Spain+41 Bernstein Autonomous LLP; Geneva, Switzerland+49 BSG France S.A.; Frankfurt, Germany+91 Sanford C. Bernstein (India) Private Limited; Mumbai, India+852 Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司; Hong Kong, China+65 Sanford C. Bernstein (Singapore) Private Limited; Singapore+81 Sanford C. Bernstein Japan KK; Tokyo, Japan",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "ef5e43bbc350caf8",
      "text": "Where this report has been prepared by research analyst(s) employed by a non- US affiliate, such analyst(s), is/are (unless otherwise expressly noted below) not registered as associated persons of Bernstein Institutional Services LLC or any other SEC- registered broker- dealer and are not licensed or qualified as research analysts with FINRA. Accordingly, such analyst(s) may not be subject to FINRA's restrictions regarding (among other things) communications by research analysts with a subject company, interactions between research analysts and investment banking personnel, participation by research analysts in solicitation and marketing activities relating to investment banking transactions, public appearances by research analysts, and trading securities",
      "page": 14,
      "section": null
    },
    {
      "passage_id": "e79844386aa7c5bf",
      "text": "held by a research analyst account.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "aea23b051c91d646",
      "text": "Each research analyst listed in this report, who is primarily responsible for the preparation of the content of this report, certifies that all of the views expressed in this publication accurately reflect that analyst's personal views about any and all of the subject securities or issuers and that no part of that analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views in this publication.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "80e187e24c174252",
      "text": "It is at the sole discretion of the Firm as to when to initiate, update and cease research coverage. The Firm has established, maintains and relies on information barriers to control the flow of information contained in one or more areas (i.e., the private side) within the Firm, and into other areas, units, groups or affiliates (i.e., public side) of the Firm.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ef5c805c42074f8e",
      "text": "Separate branding is maintained for \"Bernstein\" and \"Autonomous\" research products.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "9243b3955a0dd557",
      "text": "- Bernstein produces a number of different types of research products including, among others, fundamental analysis and quantitative analysis under both the \"Autonomous\" and \"Bernstein\" brands. Recommendations contained within one type of research product may differ from recommendations contained within other types of research products, whether as a result of differing time horizons, methodologies or otherwise. Furthermore, views or recommendations within a research product issued under one brand may differ from views or recommendations under the same type of research product issued under the other brand. The Research Ratings System for the two brands and other information related to those Rating Systems are included in the previous section.- Autonomous operates as a separate business unit within the following entities: Bernstein Institutional Services LLC, Bernstein Autonomous LLP, Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 and Sanford C. Bernstein (India) Private Limited. For information relating to \"Autonomous\" branded products (including certain Sales materials) please visit: www.autonomous.com. For information relating to Bernstein branded products please visit: www.bernsteinresearch.com.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "ec083b17b1d42c76",
      "text": "Analysts are compensated based on aggregate contributions to the research franchise as measured by account penetration, productivity and proactivity of investment ideas. No analysts are compensated based on performance in, or contributions to, generating investment banking revenues.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "f6fc3c475d8a40c0",
      "text": "This report has been produced by an independent analyst as defined in Article 3 (1)(34)(i) of EU 596/2014 Market Abuse Regulation (\"MAR\") and the same article of MAR as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "9f5f08e1dcce0860",
      "text": "To our readers in the United States: Bernstein Institutional Services LLC, a broker- dealer registered with the U.S. Securities and Exchange Commission (\"SEC\") and a member of the U.S. Financial Industry Regulatory Authority, Inc. (\"FINRA\") is distributing this publication in the United States and accepts responsibility for its contents. Where this material contains an analysis of debt product(s), such material is intended only for institutional investors and is not subject to the US independence and disclosure standards applicable to debt research prepared for retail investors.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "6e58dc6d4486effb",
      "text": "Bernstein Institutional Services LLC may act as principal for its own account or as agent for another person (including an affiliate) in sales or purchases of any security which is a subject of this report. This report does not purport to meet the objectives or needs of any specific individuals, entities or accounts.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "60339697b31bd8b9",
      "text": "To our readers in Canada: If this publication pertains to a Canadian domiciled company, it is being distributed in Canada by Sanford C. Bernstein (Canada) Limited, which is licensed and regulated by the Canadian Investment Regulatory Organization. If the publication pertains to a non- Canadian domiciled company, it is being distributed by Bernstein Institutional Services LLC, which is licensed and regulated by both the SEC and FINRA, into Canada under the International Dealers Exemption.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "12bcdcbefd831158",
      "text": "This document may not be passed onto any person in Canada unless that person qualifies as \"permitted client\" as defined in Section 1.1 of NI 31- 103.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "4269b097e218c835",
      "text": "To our readers in Brazil: This report has been prepared by Bernstein Institutional Services LLC, and Banco BTG Pactual S.A. (\"BTG\") is responsible for the distribution of this report in Brazil.",
      "page": 15,
      "section": null
    },
    {
      "passage_id": "2207021742a4d601",
      "text": "To readers in the United Kingdom: This publication has been issued or approved for issue in the United Kingdom by Bernstein Autonomous LLP, authorised and regulated by the Financial Conduct Authority and located at 60 London Wall, London EC2M 5SH, +44 (0)20- 7170- 5000. Registered in England & Wales No OC343985.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "6c218ff3e9e879e1",
      "text": "This document is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the \"Financial Promotion Order\"), (ii) are persons falling within Article 49(2)(a) to (d) (\"high net worth companies, unincorporated associations, etc.\") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as \"relevant persons\"). This document is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this document relates is available only to relevant persons and will be engaged in only with relevant persons.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "7fc49d88bd05b455",
      "text": "To our readers in the member states of the EEA: This publication is being distributed by BSG France SA, which is authorised and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and Autorité des Marchés Financiers (AMF).",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "c2499f22663be25b",
      "text": "To our readers in Hong Kong: This publication is being distributed in Hong Kong by Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, which is licensed and regulated by the Hong Kong Securities and Futures Commission (Central Entity No. AXC846) to carry out Type 4 (Advising on Securities) regulated activities and subject to the licensing conditions mentioned in the SFC Public Register (https://www.sfc.hk/publicregWeb/corp/AXC846/details)). This publication is solely for professional investors, as defined in the Securities and Futures Ordinance (Cap. 571).",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "27b11fd50235593e",
      "text": "To our readers in Singapore: This publication is being distributed in Singapore by Sanford C. Bernstein (Singapore) Private Limited, only to accredited investors or institutional investors, as defined in the Securities and Futures Act 2001 of Singapore (\"SFA\"). Recipients in Singapore should contact Sanford C. Bernstein (Singapore) Private Limited in respect of matters arising from, or in connection with, this publication. Sanford C. Bernstein (Singapore) Private Limited is regulated by the Monetary Authority of Singapore and licensed under the SFA as a capital markets services licence holder for dealing in capital markets products that are securities and collective investment schemes and an exempt financial adviser for advising on, issuing and promulgating analyses and reports on securities. Sanford C. Bernstein (Singapore) Private Limited is registered in Singapore with Company Registration No. 20213710W and located at One Raffles Quay, #27- 11 South Tower, Singapore 048583, +65- 6230- 4612.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "61ad87a927d48a88",
      "text": "To our readers in the People's Republic of China: The securities referred to in this document are not being offered or sold and may not be offered or sold, directly or indirectly, in the People's Republic of China (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan, the \"PRC\") in contravention of any applicable laws of the PRC.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "56240745c243b2f6",
      "text": "This document does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC to any person to whom it is unlawful to make the offer or solicitation in the PRC.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "42f21ac3b369df92",
      "text": "We do not represent that this document may be lawfully distributed, or that any securities may be lawfully offered, in compliance with any applicable registration or other requirements in the PRC, or pursuant to an exemption available thereunder, or assume any responsibility for facilitating any such distribution or offering. In particular, no action has been taken by us which would permit a public offering of any securities or distribution of this document in the PRC. Accordingly, the securities are not being offered or sold within the PRC by means of this document or any other document. Neither this document nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with any applicable laws and regulations.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "2aaf1cc3853f6957",
      "text": "To our readers in Japan: This publication is being distributed in Japan by Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社), which is registered in Japan as a Financial Instruments Business Operator with the Kanto Local Finance Bureau (registration number: The Director- General of Kanto Local Finance Bureau (FIBO) No.3387) and regulated by the Financial Services Agency. It is also a member of Japan Investment Advisers Association. This publication is solely for qualified institutional investors in Japan only, as defined in Article 2, paragraph (3), items (i) of the Financial Instruments and Exchange Act.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "0b2dd882d666de6e",
      "text": "For the institutional client readers in Japan who have been granted access to the Bernstein website by Daiwa Securities Group Inc. (\"Daiwa\"), your access to this document should not be construed as meaning that Bernstein is providing you with investment advice for any purposes. Whilst Bernstein has prepared this document, your relationship is, and will remain with, Daiwa, and Bernstein has neither any contractual relationship with you nor any obligations towards you.",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "b00cb1e66a7261d4",
      "text": "To our readers in Australia: Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is responsible for distributing research in Australia. It is regulated by the Securities and Exchange Commission under U.S. laws, by the Financial Conduct Authority under U.K. laws, which differs from Australian laws. Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司 is exempt from the requirement to hold an Australian financial services license under the Corporations Act 2001 in respect of the provision of the",
      "page": 16,
      "section": null
    },
    {
      "passage_id": "fcdd633e872a5779",
      "text": "following financial services to wholesale clients:",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "658e0e2deffcfc51",
      "text": "- providing financial product advice;- dealing in a financial product;- making a market for a financial product; and- providing a custodial or depository service.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "b47a729707e0e160",
      "text": "To our readers in India: This publication is being distributed in India by Sanford C. Bernstein (India) Private Limited (SCB India) which is licensed and regulated by Securities and Exchange Board of India (\"SEBI\") as a research analyst entity under the SEBI (Research Analyst) Regulations, 2014, having registration no. INH000006378 and as a stock broker having registration no. INZ000213537. SCB India is currently engaged in the business of providing research and stock broking services. Please refer to www.bernsteinresearch.in for more information.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "da10dc8155286fbe",
      "text": "- SCB India is a Private limited company incorporated under the Companies Act, 2013, on April 12, 2017 bearing corporate identification number U65999MH2017FTC293762, and registered office at Level 3A, 4th Floor, First International Financial Centre, Plot Nos C-54 and C-55, G Block, Near CBI Office, Bandra Kurla Complex, Bandra (East), Mumbai 400098, Maharashtra, India (Phone No: +91-22-68421401).",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "761fa90f11458808",
      "text": "- SCB India does not have any disciplinary history as on the date of this report.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "9eac16ee7a9d4f58",
      "text": "- Except as noted above, SCB India and/or its Associates (i.e., affiliates/group companies), the Research Analysts authoring this report, and their relatives",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "67c7ea2b60616572",
      "text": "- do not have any financial interest in the subject company- do not have actual/beneficial ownership of one percent or more in securities of the subject company;- is not engaged in any investment banking activities for Indian companies, as such;- have not managed or co-managed a public offering in the past twelve months for any Indian companies;- have not received any compensation for investment banking services or merchant banking services from the subject company in the past 12 months;- have not received compensation for brokerage services from the subject company in the past twelve months;- have not received any compensation or other benefits from the subject company or third party related to the specific recommendations or views in this report; and- do not currently, but may in the future, act as a market maker in the financial instruments of the companies covered in the report.- do not have any conflict of interest in the subject company as of the date of this report.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "89a737bdb6e3324d",
      "text": "- Except as noted above, the subject company has not been a client of SCB India during twelve months preceding the date of distribution of this research report. Neither SCB India nor its Associates (i.e., affiliates/group companies) have received compensation for products or services other than investment banking, merchant banking or brokerage services from the subject company in the past twelve months.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "97ed983afe8c2791",
      "text": "- The principal research analyst(s) who prepared this report, members of the analysts' team, and members of their households are not an officer, director, employee or advisory board member of the companies covered in the report.",
      "page": 17,
      "section": null
    },
    {
      "passage_id": "a757a89c222b2717",
      "text": "- The investor charter of SCB India is available on its website and may be accessed at Sanford C. Bernstein (India) Private Limited (bernsteinresearch.in)",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "7f14ed1d2c743f3e",
      "text": "- Disclaimer: Registration granted by SEBI, and certification from NISM, is in no way a guarantee of performance of the intermediary or provide any assurance of returns to investors. Investments in securities market are subject to market risks. Read all the related documents carefully before investing.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "2e61366cf2b29d5a",
      "text": "To our readers in Switzerland: This document is provided in Switzerland by or through Bernstein Autonomous LLP, and is provided only to qualified investors as defined in article 10 of the Swiss Collective Investment Scheme Act (\"CISA\") and related provisions of the Collective Investment Scheme Ordinance and in strict compliance with applicable Swiss law and regulations. The products mentioned in this document may not be suitable for all types of investors. This document is based on the Directives on the Independence of Financial Research issued by the Swiss Bankers Association (SBA) in January 2008.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "9b8f6778714b0e55",
      "text": "To our readers in the Middle East: Bernstein Autonomous LLP, DIFC branch has its principal office at Gate Village 06, DIFC, Dubai, UAE. Bernstein Autonomous LLP, DIFC branch is regulated by the Dubai Financial Services Authority (DFSA) with the registration number F008549 and is provisioned for Arranging Deals in Investments and Advising on Financial Products. All communications and services are directed at Professional Clients and Market Counterparties only (as defined in the DFSA rulebook). Persons other than Professional Clients and Market Counterparties, such as Retail Clients, are not the intended recipients of our communications or services.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "1a2e602641bc5582",
      "text": "All research publications are disseminated to our clients through posting on the firm's password protected websites, bernsteinresearch.com and autonomous.com. Certain, but not all, research publications are also made available to clients through third- party vendors or redistributed to clients through alternate electronic means as a convenience.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "7d03e4c13fdbca85",
      "text": "This publication has been published and distributed in accordance with the Firm's policy for management of conflicts of interest in investment research, a copy of which is available from Bernstein Institutional Services LLC, Director of Compliance, 245 Park Avenue, New York, NY 10167. Additional disclosures and information regarding Bernstein's business are available on our website www.bernsteinresearch.com.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "3758e5969ff4234c",
      "text": "The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. This publication is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of, or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject any of the entities referenced herein or any of their subsidiaries or affiliates to any registration or licensing requirement within such jurisdiction. This publication is based upon public sources we believe to be reliable, but no representation is made by us that the publication is accurate or complete. We do not undertake to advise you of any change in the reported information or in the opinions herein. This publication was prepared and issued by entity referred to herein for distribution to eligible counterparties or professional clients. This publication is not an offer to buy or sell any security, and it does not constitute investment, legal or tax advice. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with their professional advisors in light of their specific circumstances. The value of investments may fluctuate, and investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to exchange rate movements. Information about past performance of an investment is not necessarily a guide to, indicator of, or assurance of, future performance.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "141906dc0e80c04c",
      "text": "This report is directed to and intended only for our clients who are \"eligible counterparties\", \"professional clients\", \"institutional investors\" and/or \"professional investors\" as defined by the aforementioned regulators, and must not be redistributed to retail clients as defined by the aforementioned regulators. Retail clients who receive this report should note that the services of the entities noted herein are not available to them and should not rely on the material herein to make an investment decision. The result of such act will not hold the entities noted herein liable for any loss thus incurred as the entities noted herein are not registered/ authorised/ licensed to deal with retail clients and will not enter into any contractual agreement/arrangement with retail clients. This report is provided subject to the terms and conditions of any agreement that the clients may have entered into with the entities noted herein. All research reports are disseminated on a simultaneous basis to eligible clients through electronic publication to our client portal. The information is private and confidential and for the use of the clients only.",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "a2dd9306fbf465ff",
      "text": "This report has been prepared for information purposes only and is based on current public information that we consider reliable, but the entities noted herein do not warrant or represent (express or implied) as to the sources of information or data contained herein are accurate, complete, not misleading or as to its fitness for the purpose intended even though the entities noted herein",
      "page": 18,
      "section": null
    },
    {
      "passage_id": "6433effbf5fd6028",
      "text": "rely on reputable or trustworthy data providers, it should not be relied upon as such. Opinions expressed are the author(s)' current opinions as of the date appearing on the material only and we do not undertake to advise you of any change in the reported information or in the opinions herein.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "1aa9b4f187e8a55d",
      "text": "This publication was prepared and issued by the entity referred to herein for distribution to eligible counterparties or professional clients. The information in this report is intended for general circulation and does not constitute an offer to buy or sell any security, investment, legal or tax advice nor a personal recommendation, as defined by any of the aforementioned regulators. It does not take into account the particular investment objectives, financial situations, or needs of individual investors. The report has not been reviewed by any of the aforementioned regulators and does not represent any official recommendation from the aforementioned regulators. The investments referred to herein may not be suitable for you. Investors must make their own investment decisions in consultation with advice sought from a financial adviser regarding the suitability of the investment product, taking into account the specific investment objectives, financial situation or particular needs of any recipient of the recommendation, before the recipient makes a commitment to purchase the investment product.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "c5c443cd945813c4",
      "text": "The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The information in this report does not constitute, or form part of, any offer to sell or issue, or any offer to purchase or subscribe for shares, or to induce engage in any other investment activity. The value of any securities or financial instruments mentioned in this report may fluctuate subject to market conditions. Information about past performance of an investment is not necessarily a guide to, indicative of, or assurance of future performance. Estimates of future performance mentioned by the research analyst in this report are based on assumptions that may not be realized due to unforeseen factors like market volatility/fluctuation. In relation to securities or financial instruments denominated in a foreign currency other than the clients' home currency, movements in exchange rates will have an effect on the value, either favorable or unfavorable. Before acting on any recommendations in this report, recipients should consider the appropriateness of investing in the subject securities or financial instruments mentioned in this report and, if necessary, seek for independent professional advice.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "8eec875c3fd538ac",
      "text": "The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors where that permission profile is not consistent with the licenses held by the entities noted herein. This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject the entities noted herein to any regulation or licensing requirement within such jurisdiction.",
      "page": 19,
      "section": null
    },
    {
      "passage_id": "9ed24283b82ffe35",
      "text": "No part of this material may be reproduced, distributed or transmitted or otherwise made available without prior consent of the entities noted herein. Copyright Bernstein Institutional Services LLC Bernstein Autonomous LLP, BSG France S.A., Sanford C. Bernstein (Hong Kong) Limited 盛博香港有限公司, Sanford C. Bernstein (Canada) Limited, Sanford C. Bernstein (India) Private Limited (SEBI registration no. INH000006378), Sanford C. Bernstein (Singapore) Private Limited and Sanford C. Bernstein Japan KK (サンフォード・C・バーンスタイン株式会社). All rights reserved. The trademarks and service marks contained herein are the property of their respective owners. Any unauthorized use or disclosure is strictly prohibited. The entities noted herein may pursue legal action if the unauthorized use results in any defamation and/or reputational risk to the entities noted herein and research published under the Bernstein and Autonomous brands.",
      "page": 19,
      "section": null
    }
  ],
  "entities": [
    {
      "entity_id": "af0234deee25916b",
      "name": "Adjusted EPS",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7e2d4425303bea59",
      "name": "Administrative Regions",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "6afac77b7140b4ce",
      "name": "Advisers Association",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "8d9681c52dfbdc52",
      "name": "And Zepbound",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "bf450f9d7cbb2e1d",
      "name": "Arranging Deals",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2ebc1f6a39f03ec8",
      "name": "Asia Pacific",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "e77b2a44ee60341f",
      "name": "Aug Source",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "18ff676d9d8cf555",
      "name": "Autonomous Brand",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "c160d65049f4dfd5",
      "name": "Autonomous LLP",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "fd236f518ccc816a",
      "name": "BRAND\n\nNBRx",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5a165af17b571df3",
      "name": "BSG France",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "f0c4286f4d23d3fd",
      "name": "Banco BTG",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dc2c783d2ec3346b",
      "name": "Bandra Kurla",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "abef6f4f10fd10f6",
      "name": "Banks And",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "2de3ec6fb4398605",
      "name": "Bernstein & Co",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "5b2e8ee5089f48f3",
      "name": "Bernstein Analysis",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "02c62a0dceca70db",
      "name": "Bernstein Autonomous",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "d6ff22152f52aa09",
      "name": "Bernstein Brand",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "dcdf65cc6eabf8fb",
      "name": "Bernstein Institutional",
      "type": "company",
      "aliases": []
    },
    {
      "entity_id": "7832fd920d7f76b4",
      "name": "Bernstein Japan",
      "type": "company",
      "aliases": []
    }
  ],
  "data": {
    "figures": [
      {
        "type": "line",
        "title": "GLP-1 TRx Weekly (data up to Aug-22)",
        "page": 3,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "03-Feb-23",
              "03-Apr-23",
              "03-Jun-23",
              "03-Aug-23",
              "03-Oct-23",
              "03-Dec-23",
              "03-Feb-24",
              "03-Apr-24",
              "03-Jun-24",
              "03-Aug-24",
              "03-Oct-24",
              "03-Dec-24",
              "03-Feb-25",
              "03-Apr-25",
              "03-Jun-25",
              "03-Aug-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 700000
            }
          }
        },
        "series": [
          {
            "name": "MOUNJARO",
            "unit": null,
            "values": [
              350000,
              380000,
              400000,
              450000,
              480000,
              500000,
              550000,
              580000,
              600000,
              590000,
              550000,
              580000,
              600000,
              620000,
              630000,
              600000
            ]
          },
          {
            "name": "OZEMPIC",
            "unit": null,
            "values": [
              250000,
              280000,
              270000,
              260000,
              250000,
              280000,
              300000,
              350000,
              400000,
              450000,
              480000,
              400000,
              500000,
              550000,
              580000,
              550000
            ]
          },
          {
            "name": "ZEPBOUND",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              50000,
              100000,
              150000,
              200000,
              250000,
              300000,
              350000,
              400000,
              450000,
              400000
            ]
          },
          {
            "name": "WEGOVY",
            "unit": null,
            "values": [
              150000,
              180000,
              200000,
              220000,
              200000,
              180000,
              150000,
              180000,
              200000,
              220000,
              250000,
              280000,
              300000,
              320000,
              330000,
              330000
            ]
          },
          {
            "name": "TRULICITY",
            "unit": null,
            "values": [
              280000,
              270000,
              260000,
              250000,
              240000,
              230000,
              220000,
              210000,
              200000,
              190000,
              180000,
              170000,
              160000,
              160000,
              150000,
              150000
            ]
          }
        ],
        "figure_id": "f9de0a7a3962bade",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 8,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Dec-2023",
              "Jan-2024",
              "Feb-2024",
              "Mar-2024",
              "Apr-2024",
              "May-2024",
              "Jun-2024",
              "Jul-2024",
              "Aug-2024",
              "Sep-2024",
              "Oct-2024",
              "Nov-2024",
              "Dec-2024",
              "Jan-2025",
              "Feb-2025",
              "Mar-2025",
              "Apr-2025",
              "May-2025",
              "Jun-2025",
              "Jul-2025",
              "Aug-2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 100
            }
          }
        },
        "series": [
          {
            "name": "Zepbound",
            "unit": "%",
            "values": [
              0,
              20,
              37,
              41,
              35,
              30,
              39,
              38,
              39,
              41,
              44,
              47,
              50,
              53,
              57,
              60,
              62,
              64,
              65,
              58,
              58
            ]
          },
          {
            "name": "Wegovy",
            "unit": "%",
            "values": [
              100,
              80,
              65,
              60,
              69,
              62,
              59,
              58,
              57,
              55,
              53,
              51,
              49,
              45,
              42,
              39,
              37,
              35,
              34,
              42,
              42
            ]
          }
        ],
        "figure_id": "1d03709776c4156a",
        "provenance": {
          "page": 8
        }
      },
      {
        "type": "line",
        "title": "Weekly Switch Rx (GLP-1s)",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "02/06/2023",
              "02/08/2023",
              "02/10/2023",
              "02/12/2023",
              "02/02/2024",
              "02/04/2024",
              "02/06/2024",
              "02/08/2024",
              "02/10/2024",
              "02/12/2024",
              "02/02/2025",
              "02/04/2025",
              "02/06/2025",
              "02/08/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 60000
            }
          }
        },
        "series": [
          {
            "name": "MOUNJARO LILLY",
            "unit": null,
            "values": [
              41000,
              37000,
              30000,
              18000,
              32000,
              47000,
              50000,
              32000,
              27000,
              28000,
              32000,
              35000,
              37000,
              22000
            ]
          },
          {
            "name": "OZEMPIC NOVO NORDISK",
            "unit": null,
            "values": [
              15000,
              18000,
              25000,
              37000,
              38000,
              25000,
              22000,
              25000,
              20000,
              27000,
              28000,
              32000,
              35000,
              30000
            ]
          },
          {
            "name": "WEGOVY NOVO NORDISK",
            "unit": null,
            "values": [
              2000,
              2000,
              1000,
              8000,
              9000,
              6000,
              4000,
              6000,
              8000,
              10000,
              12000,
              14000,
              15000,
              18000
            ]
          },
          {
            "name": "ZEPBOUND LILLY",
            "unit": null,
            "values": [
              1000,
              1000,
              1000,
              1000,
              2000,
              3000,
              3000,
              3000,
              3000,
              3000,
              3000,
              5000,
              10000,
              15000
            ]
          }
        ],
        "figure_id": "0e108256d1198a5c",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Feb-2023",
              "May-2023",
              "Aug-2023",
              "Nov-2023",
              "Feb-2024",
              "May-2024",
              "Aug-2024",
              "Nov-2024",
              "Feb-2025",
              "May-2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0.0,
              "max": 80.0
            }
          }
        },
        "series": [
          {
            "name": "M+Z together",
            "unit": "%",
            "values": [
              71.5,
              73.0,
              73.5,
              68.0,
              61.0,
              65.0,
              62.0,
              58.0,
              52.0,
              46.0
            ]
          },
          {
            "name": "O+W together",
            "unit": "%",
            "values": [
              29.0,
              27.0,
              26.0,
              32.0,
              39.0,
              34.5,
              38.0,
              45.0,
              51.0,
              55.0
            ]
          }
        ],
        "figure_id": "599d33401e77d99e",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Feb-2023",
              "May-2023",
              "Aug-2023",
              "Nov-2023",
              "Feb-2024",
              "May-2024",
              "Aug-2024",
              "Nov-2024",
              "Feb-2025",
              "May-2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0.0,
              "max": 70.0
            }
          }
        },
        "series": [
          {
            "name": "Mounjaro",
            "unit": "%",
            "values": [
              60.0,
              56.0,
              60.0,
              52.0,
              50.0,
              46.0,
              42.0,
              38.0,
              35.0,
              33.2
            ]
          },
          {
            "name": "Ozempic",
            "unit": "%",
            "values": [
              29.0,
              27.0,
              28.0,
              33.0,
              28.0,
              29.0,
              30.0,
              31.0,
              31.0,
              30.9
            ]
          },
          {
            "name": "Zepbound",
            "unit": "%",
            "values": [
              0.0,
              0.0,
              0.0,
              0.0,
              7.0,
              10.0,
              15.0,
              20.0,
              23.0,
              20.8
            ]
          },
          {
            "name": "Wegovy",
            "unit": "%",
            "values": [
              10.0,
              17.0,
              13.0,
              10.0,
              12.0,
              13.0,
              14.0,
              12.0,
              13.0,
              15.1
            ]
          }
        ],
        "figure_id": "a680aad32446f08a",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": "Eli Lilly & Co (LLY) Rating History for Bernstein as of 08/28/2025",
        "page": 15,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Oct 22",
              "Jan 23",
              "Apr 23",
              "Jul 23",
              "Oct 23",
              "Jan 24",
              "Apr 24",
              "Jul 24",
              "Oct 24",
              "Jan 25",
              "Apr 25",
              "Jul 25"
            ]
          },
          "y": {
            "unit": "$",
            "range": {
              "min": 200,
              "max": 1200
            }
          }
        },
        "series": [
          {
            "name": "Closing Price",
            "unit": "$",
            "values": [
              300,
              350,
              300,
              400,
              550,
              650,
              800,
              900,
              750,
              800,
              700,
              750
            ]
          },
          {
            "name": "Price Target",
            "unit": "$",
            "values": [
              300,
              300,
              300,
              300,
              300,
              300,
              300,
              300,
              1100,
              1100,
              1100,
              1100
            ]
          }
        ],
        "figure_id": "3c414d60a895f699",
        "provenance": {
          "page": 15
        }
      },
      {
        "type": "line",
        "title": "Weekly Switch Rx (GLP-1s)",
        "page": 5,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "02/06/2023",
              "02/08/2023",
              "02/10/2023",
              "02/12/2023",
              "02/02/2024",
              "02/04/2024",
              "02/06/2024",
              "02/08/2024",
              "02/10/2024",
              "02/12/2024",
              "02/02/2025",
              "02/04/2025",
              "02/06/2025",
              "02/08/2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 35000
            }
          }
        },
        "series": [
          {
            "name": "WEGOVY NOVO NORDISK",
            "unit": null,
            "values": [
              2500,
              2000,
              2500,
              1500,
              1000,
              2500,
              4000,
              7500,
              5500,
              4000,
              3000,
              2500,
              2000,
              2000,
              2000,
              2500,
              5000,
              15000,
              30000,
              15000
            ]
          }
        ],
        "figure_id": "08df02a677671f3b",
        "provenance": {
          "page": 5
        }
      },
      {
        "type": "line",
        "title": "GLP-1 NRx Weekly (data up to Aug-22)",
        "page": 3,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "03-Feb-23",
              "03-Apr-23",
              "03-Jun-23",
              "03-Aug-23",
              "03-Oct-23",
              "03-Dec-23",
              "03-Feb-24",
              "03-Apr-24",
              "03-Jun-24",
              "03-Aug-24",
              "03-Oct-24",
              "03-Dec-24",
              "03-Feb-25",
              "03-Apr-25",
              "03-Jun-25",
              "03-Aug-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 350000
            }
          }
        },
        "series": [
          {
            "name": "MOUNJARO",
            "unit": null,
            "values": [
              190000,
              270000,
              240000,
              260000,
              200000,
              270000,
              240000,
              290000,
              260000,
              280000,
              260000,
              290000,
              280000,
              300000,
              320000,
              310000
            ]
          },
          {
            "name": "ZEPBOUND",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              50000,
              100000,
              150000,
              200000,
              250000,
              290000,
              270000,
              250000,
              280000,
              240000
            ]
          },
          {
            "name": "OZEMPIC",
            "unit": null,
            "values": [
              120000,
              130000,
              120000,
              140000,
              150000,
              160000,
              180000,
              200000,
              220000,
              240000,
              260000,
              280000,
              290000,
              300000,
              290000,
              280000
            ]
          },
          {
            "name": "WEGOVY",
            "unit": null,
            "values": [
              10000,
              10000,
              10000,
              10000,
              10000,
              10000,
              10000,
              20000,
              40000,
              80000,
              120000,
              150000,
              170000,
              180000,
              190000,
              180000
            ]
          },
          {
            "name": "TRULICITY",
            "unit": null,
            "values": [
              120000,
              110000,
              100000,
              90000,
              80000,
              70000,
              60000,
              60000,
              60000,
              60000,
              60000,
              60000,
              60000,
              60000,
              60000,
              60000
            ]
          }
        ],
        "figure_id": "534c0d79f94a1fec",
        "provenance": {
          "page": 3
        }
      },
      {
        "type": "other",
        "title": null,
        "page": 1,
        "axes": null,
        "series": [],
        "figure_id": "25a5f139aac20038",
        "provenance": {
          "page": 1
        }
      },
      {
        "type": "line",
        "title": null,
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "17-Nov-23",
              "17-Dec-23",
              "17-Jan-24",
              "17-Feb-24",
              "17-Mar-24",
              "17-Apr-24",
              "17-May-24",
              "17-Jun-24",
              "17-Jul-24",
              "17-Aug-24",
              "17-Sep-24",
              "17-Oct-24",
              "17-Nov-24",
              "17-Dec-24",
              "17-Jan-25",
              "17-Feb-25",
              "17-Mar-25",
              "17-Apr-25",
              "17-May-25",
              "17-Jun-25",
              "17-Jul-25"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 80
            }
          }
        },
        "series": [
          {
            "name": "MOUNJARO",
            "unit": "%",
            "values": [
              72,
              74,
              71,
              73,
              75,
              72,
              68,
              70,
              71,
              72,
              72,
              71,
              72,
              72,
              73,
              73,
              72,
              71,
              69,
              67,
              67
            ]
          },
          {
            "name": "OZEMPIC",
            "unit": "%",
            "values": [
              62,
              64,
              66,
              68,
              70,
              72,
              70,
              68,
              66,
              65,
              66,
              65,
              64,
              65,
              65,
              66,
              65,
              65,
              64,
              64,
              64
            ]
          },
          {
            "name": "WEGOVY",
            "unit": "%",
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              11,
              12,
              56,
              41
            ]
          },
          {
            "name": "ZEPBOUND",
            "unit": "%",
            "values": [
              18,
              36,
              33,
              30,
              28,
              25,
              24,
              23,
              24,
              25,
              26,
              27,
              28,
              27,
              26,
              25,
              21,
              22,
              23,
              22,
              23
            ]
          }
        ],
        "figure_id": "1fdfb546e203840b",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": "GLP-1 TRx Weekly (data up to Aug-22)",
        "page": 7,
        "axes": {
          "x": {
            "type": "time",
            "labels": [
              "03-Feb-23",
              "03-Apr-23",
              "03-Jun-23",
              "03-Aug-23",
              "03-Oct-23",
              "03-Dec-23",
              "03-Feb-24",
              "03-Apr-24",
              "03-Jun-24",
              "03-Aug-24",
              "03-Oct-24",
              "03-Dec-24",
              "03-Feb-25",
              "03-Apr-25",
              "03-Jun-25",
              "03-Aug-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 2500000
            }
          }
        },
        "series": [
          {
            "name": "Total",
            "unit": null,
            "values": [
              850000,
              950000,
              1050000,
              1000000,
              1100000,
              1000000,
              1150000,
              1250000,
              1350000,
              1450000,
              1550000,
              1650000,
              1700000,
              1850000,
              2000000,
              2050000
            ]
          }
        ],
        "figure_id": "c31d4614c41b1179",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "line",
        "title": "NBRx (Weekly) for weightloss agents (split by administration)",
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "02-Jun-2023",
              "11-Jul-2023",
              "19-Aug-2023",
              "27-Sep-2023",
              "05-Nov-2023",
              "14-Dec-2023",
              "22-Jan-2024",
              "01-Mar-2024",
              "09-Apr-2024",
              "18-May-2024",
              "26-Jun-2024",
              "04-Aug-2024",
              "12-Sep-2024",
              "21-Oct-2024",
              "29-Nov-2024",
              "07-Jan-2025",
              "15-Feb-2025",
              "26-Mar-2025",
              "04-May-2025",
              "12-Jun-2025",
              "21-Jul-2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 80000
            }
          }
        },
        "series": [
          {
            "name": "Zepbound Total",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              50000,
              63000,
              72000,
              60000,
              50000,
              60000
            ]
          },
          {
            "name": "Total Wegovy",
            "unit": null,
            "values": [
              18000,
              15000,
              12000,
              10000,
              8000,
              7000,
              10000,
              20000,
              30000,
              25000,
              22000,
              25000,
              27000,
              25000,
              20000,
              35000,
              38000,
              40000,
              35000,
              30000,
              35000
            ]
          },
          {
            "name": "Zepbound Pen",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              12000,
              15000,
              28000,
              18000,
              10000,
              20000
            ]
          },
          {
            "name": "Zepbound Vial",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              38000,
              48000,
              44000,
              42000,
              40000,
              40000
            ]
          }
        ],
        "figure_id": "b97333260809cf9f",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "area",
        "title": "Zepbound TRx by dosage",
        "page": 10,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "10-Feb-23",
              "10-Mar-23",
              "10-Apr-23",
              "10-May-23",
              "10-Jun-23",
              "10-Jul-23",
              "10-Aug-23",
              "10-Sep-23",
              "10-Oct-23",
              "10-Nov-23",
              "10-Dec-23",
              "10-Jan-24",
              "10-Feb-24",
              "10-Mar-24",
              "10-Apr-24",
              "10-May-24",
              "10-Jun-24",
              "10-Jul-24",
              "10-Aug-24",
              "10-Sep-24",
              "10-Oct-24",
              "10-Nov-24",
              "10-Dec-24",
              "10-Jan-25",
              "10-Feb-25",
              "10-Mar-25",
              "10-Apr-25",
              "10-May-25",
              "10-Jun-25",
              "10-Jul-25",
              "10-Aug-25"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 450000
            }
          }
        },
        "series": [
          {
            "name": "ZEPBOUND LILLY 15MG/0.5ML",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "ZEPBOUND LILLY 12.5MG/0.5ML",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "ZEPBOUND LILLY 10MG/0.5ML",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "ZEPBOUND LILLY 7.5MG/0.5ML",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "ZEPBOUND LILLY 5MG/0.5ML",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          },
          {
            "name": "ZEPBOUND LILLY 2.5MG/0.5ML",
            "unit": null,
            "values": [
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "a008e8c03db9782c",
        "provenance": {
          "page": 10
        }
      },
      {
        "type": "line",
        "title": "NBRx (Weekly) for GLP-1s",
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "02-Jun-2023",
              "11-Jul-2023",
              "19-Aug-2023",
              "27-Sep-2023",
              "05-Nov-2023",
              "14-Dec-2023",
              "22-Jan-2024",
              "01-Mar-2024",
              "09-Apr-2024",
              "18-May-2024",
              "26-Jun-2024",
              "04-Aug-2024",
              "12-Sep-2024",
              "21-Oct-2024",
              "29-Nov-2024",
              "07-Jan-2025",
              "15-Feb-2025",
              "26-Mar-2025",
              "04-May-2025",
              "12-Jun-2025",
              "21-Jul-2025"
            ]
          },
          "y": {
            "unit": null,
            "range": {
              "min": 0,
              "max": 80000
            }
          }
        },
        "series": [
          {
            "name": "ZEPBOL",
            "unit": null,
            "values": [
              70000,
              65000,
              60000,
              50000,
              40000,
              30000,
              45000,
              50000,
              60000,
              68000,
              55000,
              45000,
              40000,
              35000,
              45000,
              40000,
              35000,
              40000,
              50000,
              60000,
              55000
            ]
          },
          {
            "name": "MOUNJA",
            "unit": null,
            "values": [
              25000,
              28000,
              22000,
              30000,
              45000,
              35000,
              50000,
              40000,
              35000,
              40000,
              30000,
              25000,
              30000,
              40000,
              45000,
              50000,
              45000,
              35000,
              40000,
              50000,
              55000
            ]
          },
          {
            "name": "WEGOV",
            "unit": null,
            "values": [
              15000,
              18000,
              12000,
              10000,
              8000,
              10000,
              20000,
              35000,
              25000,
              30000,
              20000,
              25000,
              20000,
              25000,
              20000,
              25000,
              20000,
              25000,
              30000,
              35000,
              40000
            ]
          },
          {
            "name": "OZEMPI",
            "unit": null,
            "values": [
              18000,
              15000,
              10000,
              8000,
              5000,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0,
              0
            ]
          }
        ],
        "figure_id": "5f840e3bbc21fe32",
        "provenance": {
          "page": 4
        }
      },
      {
        "type": "line",
        "title": "GLP-1 NRx Weekly (data up to Aug-22)",
        "page": 7,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "03-Feb-23",
              "03-Apr-23",
              "03-Jun-23",
              "13-Aug-23",
              "03-Oct-23",
              "13-Dec-23",
              "23-Feb-24",
              "03-Apr-24",
              "03-Jun-24",
              "03-Aug-24",
              "03-Oct-24",
              "13-Dec-24",
              "03-Feb-25",
              "03-Apr-25",
              "03-Jun-25",
              "03-Aug-25"
            ]
          },
          "y": {
            "unit": "",
            "range": {
              "min": 0,
              "max": 1200000
            }
          }
        },
        "series": [
          {
            "name": "Total",
            "unit": "",
            "values": [
              480000,
              550000,
              650000,
              580000,
              520000,
              500000,
              600000,
              700000,
              800000,
              750000,
              850000,
              700000,
              800000,
              950000,
              1000000,
              1100000
            ]
          }
        ],
        "figure_id": "20bb1b65eb40fd6c",
        "provenance": {
          "page": 7
        }
      },
      {
        "type": "line",
        "title": "% of Weightloss NBRx's captured (Zepbound vs Wegovy)",
        "page": 4,
        "axes": {
          "x": {
            "type": "category",
            "labels": [
              "Jun-2024",
              "Jul-2024",
              "Aug-2024",
              "Sep-2024",
              "Oct-2024",
              "Nov-2024",
              "Dec-2024",
              "Jan-2025",
              "Feb-2025",
              "Mar-2025",
              "Apr-2025",
              "May-2025",
              "Jun-2025",
              "Jul-2025"
            ]
          },
          "y": {
            "unit": "%",
            "range": {
              "min": 0,
              "max": 90
            }
          }
        },
        "series": [
          {
            "name": "Zepbound (NBRx %)",
            "unit": "%",
            "values": [
              39.5,
              36.5,
              41.5,
              45.5,
              56.5,
              50.5,
              53.0,
              60.5,
              68.0,
              71.5,
              75.0,
              68.5,
              44.0,
              61.0
            ]
          }
        ],
        "figure_id": "15b6dd861b990a8a",
        "provenance": {
          "page": 4
        }
      }
    ],
    "tables": [],
    "numerical_data": [
      {
        "num_id": "8755ba26c7857e91",
        "value": 0.006,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0_0.jpg) Weekly GLP- 1 scripts are still hovering around the 2 million mark, up by a small amount (+0.6%) on last week. Wegovy scripts continue to flatten off, whilst Mounjaro climbs higher and Zepbou",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "96fd17a9ec7cb2bd",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ill tracks below the pre- 7/1 (CVS Wegovy formulary change) level. Ozempic is now in YoY decline (- 0.5%, 4 wk avg). No IQVIA data irregularities to report this week, although our 4- week average grow",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "8974b0c1fe877439",
        "value": 0.0060999999999999995,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "o account. Total scripts: Total weekly scripts for the week ending 22nd August were 2.06M, up 12k (+0.61%) from last week. The 4- week sequential growth rate for sema- ttrz was +0.9%, compared to 1.1%",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2abffe6e22572b36",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "t were 2.06M, up 12k (+0.61%) from last week. The 4- week sequential growth rate for sema- ttrz was +0.9%, compared to 1.1% last week. The 4- week YoY growth for sema- ttrz was 42.9%, slightly down fr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "9713108a7daa24e8",
        "value": 0.011000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "k (+0.61%) from last week. The 4- week sequential growth rate for sema- ttrz was +0.9%, compared to 1.1% last week. The 4- week YoY growth for sema- ttrz was 42.9%, slightly down from 45.5% last week ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "40164baf7b761751",
        "value": 0.429,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ate for sema- ttrz was +0.9%, compared to 1.1% last week. The 4- week YoY growth for sema- ttrz was 42.9%, slightly down from 45.5% last week (note that recent reporting issues may understate actual g",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b2fa16d88f6c95a0",
        "value": 0.455,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "9%, compared to 1.1% last week. The 4- week YoY growth for sema- ttrz was 42.9%, slightly down from 45.5% last week (note that recent reporting issues may understate actual growth). The company market",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "ae88dd358aef554b",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "eporting issues may understate actual growth). The company market share split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Week",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b332877f024e454b",
        "value": 0.21899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "sues may understate actual growth). The company market share split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Weekly market s",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "554c983b51aa0243",
        "value": 0.332,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ate actual growth). The company market share split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Weekly market share for Zepboun",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "53016a5737bd0fe8",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "The company market share split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Weekly market share for Zepbound stands at 21.9%, s",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "16df9c9b5b2dc9de",
        "value": 0.149,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ny market share split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Weekly market share for Zepbound stands at 21.9%, stable on ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "de747fc3dd1d3a96",
        "value": 0.302,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "e split on a TRx basis is now 55% Lilly (21.9% Zepbound, 33.2% Mounjaro) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Weekly market share for Zepbound stands at 21.9%, stable on last week. Yea",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "b8e201685739e320",
        "value": 0.21899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "o) to 45% Novo (14.9% Wegovy, 30.2% Ozempic). Zepbound: Weekly market share for Zepbound stands at 21.9%, stable on last week. Year on year growth (based on 4wk rolling avg) has dropped, partially owi",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "72730a3fb46eac83",
        "value": 1.79,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "vg) has dropped, partially owing to the underreporting during the WE 8th Aug, and currently sits at 179%. Previously this had been over 200% in May- July. Assuming the \\(\\sim 120k\\) vials been include",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "81737811441ffe3b",
        "value": 2.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "the underreporting during the WE 8th Aug, and currently sits at 179%. Previously this had been over 200% in May- July. Assuming the \\(\\sim 120k\\) vials been included in WE 8th Aug, growth would still ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "0d23c782bd5f070d",
        "value": 2.0,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "% in May- July. Assuming the \\(\\sim 120k\\) vials been included in WE 8th Aug, growth would still be 200%. However, as expected, Zepbound's exceptional growth cannot continue forever, and is mean- reve",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "5144e5524a56e7e6",
        "value": 0.62,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "inue forever, and is mean- reverting too (Exhibit 17). Mounjaro: is stably ticking along at around 62% (4- week YoY) growth, down slightly from 70%, a level at which it has been hovering at since the ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2d8e5ebb9cc8eaf1",
        "value": 0.7,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ibit 17). Mounjaro: is stably ticking along at around 62% (4- week YoY) growth, down slightly from 70%, a level at which it has been hovering at since the end of May. However, looking at Exhibit 1 and",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "1ffd151dca9150a5",
        "value": 0.332,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "be accelerating whilst the other products slightly stagnate. As a result, its market share rose to 33.2% (+0.3%). Semaglutide: Ozempic (T2D) has now recorded a second consecutive week of year- on- yea",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "994fadd45b0d9b8a",
        "value": 0.003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "elerating whilst the other products slightly stagnate. As a result, its market share rose to 33.2% (+0.3%). Semaglutide: Ozempic (T2D) has now recorded a second consecutive week of year- on- year decl",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "2a13fae2d7349ca2",
        "value": 0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") has now recorded a second consecutive week of year- on- year decline, with a 4- week average of - 0.5%. Overall, semaglutide (combining both Ozempic and Wegovy) posted 9.3% YoY growth, a slight decr",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "f0538c54e6e035f0",
        "value": 0.09300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ", with a 4- week average of - 0.5%. Overall, semaglutide (combining both Ozempic and Wegovy) posted 9.3% YoY growth, a slight decrease from 9.8% last week. Both brands are driving this slowdown, Wegov",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "144cd5a322496142",
        "value": 0.098,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "all, semaglutide (combining both Ozempic and Wegovy) posted 9.3% YoY growth, a slight decrease from 9.8% last week. Both brands are driving this slowdown, Wegovy's YoY growth moderated to 36.8%, down ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "25e90084e1867ed2",
        "value": 0.368,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "crease from 9.8% last week. Both brands are driving this slowdown, Wegovy's YoY growth moderated to 36.8%, down from 38.0% last week, though this remains above the 23% low seen at the end of June. Not",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "7fe20957963a1fb0",
        "value": 0.38,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "last week. Both brands are driving this slowdown, Wegovy's YoY growth moderated to 36.8%, down from 38.0% last week, though this remains above the 23% low seen at the end of June. Note: We'd caution i",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "c8b803cfc5aac5db",
        "value": 0.23,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "n, Wegovy's YoY growth moderated to 36.8%, down from 38.0% last week, though this remains above the 23% low seen at the end of June. Note: We'd caution interpretation of 4 weekly average values given ",
        "provenance": {
          "page": 0
        }
      },
      {
        "num_id": "438ca8294653b5db",
        "value": 0.055999999999999994,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>123,834</td><td>64,352</td><td>74,161</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>5.6%</td><td>2.8%</td><td>3.1%</td></tr><tr><td>Zepbound</td><td>1,433,535</td><td>1,739,051</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b73aa6b667621be4",
        "value": 0.027999999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "4</td><td>64,352</td><td>74,161</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>5.6%</td><td>2.8%</td><td>3.1%</td></tr><tr><td>Zepbound</td><td>1,433,535</td><td>1,739,051</td><td>1,629,578</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "f53c56d6f62dc4e9",
        "value": 0.031,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "352</td><td>74,161</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>5.6%</td><td>2.8%</td><td>3.1%</td></tr><tr><td>Zepbound</td><td>1,433,535</td><td>1,739,051</td><td>1,629,578</td><td>1,553,1",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ad30087ce64464c6",
        "value": 0.213,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>305,516</td><td>109,473</td><td>76,414</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>21.3%</td><td>-6.3%</td><td>-4.7%</td></tr><tr><td>M+Z together</td><td>3,649,365</td><td>4,078,715<",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "79238423b45c6ae3",
        "value": -0.063,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>109,473</td><td>76,414</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>21.3%</td><td>-6.3%</td><td>-4.7%</td></tr><tr><td>M+Z together</td><td>3,649,365</td><td>4,078,715</td><td>4,033,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "3c0739a5b90991af",
        "value": -0.047,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3</td><td>76,414</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>21.3%</td><td>-6.3%</td><td>-4.7%</td></tr><tr><td>M+Z together</td><td>3,649,365</td><td>4,078,715</td><td>4,033,594</td><td>4,",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b24a560b101d8ad7",
        "value": 0.11800000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>429,350</td><td>45,121</td><td>2,253</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>11.8%</td><td>-1.1%</td><td>-0.1%</td></tr><tr><td>Other LLY (trulicity)</td><td>640,469</td><td>642",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "72cf68e48209d073",
        "value": -0.011000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>45,121</td><td>2,253</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>11.8%</td><td>-1.1%</td><td>-0.1%</td></tr><tr><td>Other LLY (trulicity)</td><td>640,469</td><td>642,198</td><td>6",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "d58b9b5b1b7c4b54",
        "value": -0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "21</td><td>2,253</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>11.8%</td><td>-1.1%</td><td>-0.1%</td></tr><tr><td>Other LLY (trulicity)</td><td>640,469</td><td>642,198</td><td>631,515</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6cc54b7ba987de12",
        "value": 0.003,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "></td><td>1,729</td><td>10,683</td><td>8,254</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>0.3%</td><td>-1.7%</td><td>-1.3%</td></tr><tr><td>Ozempic</td><td>2,342,846</td><td>2,381,526</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "606c49973e4100bf",
        "value": -0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "29</td><td>10,683</td><td>8,254</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>0.3%</td><td>-1.7%</td><td>-1.3%</td></tr><tr><td>Ozempic</td><td>2,342,846</td><td>2,381,526</td><td>2,328,555</",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "92b277a5b1da40e8",
        "value": -0.013000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "683</td><td>8,254</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>0.3%</td><td>-1.7%</td><td>-1.3%</td></tr><tr><td>Ozempic</td><td>2,342,846</td><td>2,381,526</td><td>2,328,555</td><td>2,305,2",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9baecbf2c2973c93",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>38,680</td><td>52,971</td><td>23,280</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>1.7%</td><td>-2.2%</td><td>-1.0%</td></tr><tr><td>Wegovy</td><td>858,206</td><td>924,222</td><td>1,0",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "31e71a99ce910548",
        "value": -0.022000000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0</td><td>52,971</td><td>23,280</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>1.7%</td><td>-2.2%</td><td>-1.0%</td></tr><tr><td>Wegovy</td><td>858,206</td><td>924,222</td><td>1,035,008</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "57bfe3540562d7c4",
        "value": -0.01,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "71</td><td>23,280</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>1.7%</td><td>-2.2%</td><td>-1.0%</td></tr><tr><td>Wegovy</td><td>858,206</td><td>924,222</td><td>1,035,008</td><td>1,126,134</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "1b88525579273c3f",
        "value": 0.077,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>66,016</td><td>110,786</td><td>91,126</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>7.7%</td><td>12.0%</td><td>8.8%</td></tr><tr><td>O+W together</td><td>3,201,052</td><td>3,305,748</t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6aa8e6b66f48f899",
        "value": 0.12,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>110,786</td><td>91,126</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>7.7%</td><td>12.0%</td><td>8.8%</td></tr><tr><td>O+W together</td><td>3,201,052</td><td>3,305,748</td><td>3,363,5",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "cc849f8d00b12667",
        "value": 0.08800000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "86</td><td>91,126</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>7.7%</td><td>12.0%</td><td>8.8%</td></tr><tr><td>O+W together</td><td>3,201,052</td><td>3,305,748</td><td>3,363,563</td><td>3,4",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "ab4cae29978eb24d",
        "value": 0.033,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>104,696</td><td>57,815</td><td>67,846</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>3.3%</td><td>1.7%</td><td>2.0%</td></tr><tr><td>Other Novo (Saxenda/Victoza)</td><td>10,814</td><td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "6dafb627f98cd547",
        "value": 0.017,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6</td><td>57,815</td><td>67,846</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>3.3%</td><td>1.7%</td><td>2.0%</td></tr><tr><td>Other Novo (Saxenda/Victoza)</td><td>10,814</td><td>9,665</td><td",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b87f6b7d42f1445e",
        "value": 0.02,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "815</td><td>67,846</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>3.3%</td><td>1.7%</td><td>2.0%</td></tr><tr><td>Other Novo (Saxenda/Victoza)</td><td>10,814</td><td>9,665</td><td>8,900</td><t",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b2fd62576a6a14f8",
        "value": -0.106,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td></td><td>1,149</td><td>765</td><td>1,957</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>-10.6%</td><td>-7.9%</td><td>22.0%</td></tr><tr><td>M+Z+O+W</td><td>6,850,417</td><td>7,384,463</td>",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "9e30e66c836560e7",
        "value": -0.079,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "149</td><td>765</td><td>1,957</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>-10.6%</td><td>-7.9%</td><td>22.0%</td></tr><tr><td>M+Z+O+W</td><td>6,850,417</td><td>7,384,463</td><td>7,397,157</",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b492189a9a5aea4c",
        "value": 0.22,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "5</td><td>1,957</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>-10.6%</td><td>-7.9%</td><td>22.0%</td></tr><tr><td>M+Z+O+W</td><td>6,850,417</td><td>7,384,463</td><td>7,397,157</td><td>7,462,7",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "18021cb7269563d9",
        "value": 0.078,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>534,046</td><td>12,694</td><td>65,593</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>7.8%</td><td>0.2%</td><td>0.9%</td></tr></table> Source: IQVIA, Bernstein analysis # TOTAL GLP1 SCRI",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "b3e331eaa42825f9",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6</td><td>12,694</td><td>65,593</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>7.8%</td><td>0.2%</td><td>0.9%</td></tr></table> Source: IQVIA, Bernstein analysis # TOTAL GLP1 SCRIPT TRENDS<｜en",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "c51f89a7c4907ea2",
        "value": 0.009000000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "694</td><td>65,593</td></tr><tr><td>vs prior 4 weeks (%)</td><td></td><td>7.8%</td><td>0.2%</td><td>0.9%</td></tr></table> Source: IQVIA, Bernstein analysis # TOTAL GLP1 SCRIPT TRENDS<｜end▁of▁sentence",
        "provenance": {
          "page": 5
        }
      },
      {
        "num_id": "afefcde6347dd244",
        "value": 0.306,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ks %</td><td>Past 12 weeks %</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>630,231</td><td>30.6%</td><td>30.6%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>20.2",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a268f4741ace0d6d",
        "value": 0.306,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ast 12 weeks %</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>630,231</td><td>30.6%</td><td>30.6%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>20.2%</td><td>19.2",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a22ad8d63b681fe7",
        "value": 0.299,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>630,231</td><td>30.6%</td><td>30.6%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>20.2%</td><td>19.2%</td><td>20.4",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7915131391fbd1b4",
        "value": 0.20199999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>30.6%</td><td>30.6%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>20.2%</td><td>19.2%</td><td>20.4%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>155,514</td><td>7.6",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "5f1fedc2e36edad6",
        "value": 0.192,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>30.6%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>20.2%</td><td>19.2%</td><td>20.4%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>155,514</td><td>7.6%</td><td>7.7%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e1bf732f4f71a343",
        "value": 0.204,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>20.2%</td><td>19.2%</td><td>20.4%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>155,514</td><td>7.6%</td><td>7.7%</td><td>7.8%<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0b4d1ce95d003362",
        "value": 0.076,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>20.2%</td><td>19.2%</td><td>20.4%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>155,514</td><td>7.6%</td><td>7.7%</td><td>7.8%</td></tr><tr><td>Total</td><td>LLY</td><td>1,201,603</td><td>58.3%</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c5a447cefe5223a3",
        "value": 0.077,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19.2%</td><td>20.4%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>155,514</td><td>7.6%</td><td>7.7%</td><td>7.8%</td></tr><tr><td>Total</td><td>LLY</td><td>1,201,603</td><td>58.3%</td><td>57.5%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0a890e4a5539c8a4",
        "value": 0.078,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>20.4%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>155,514</td><td>7.6%</td><td>7.7%</td><td>7.8%</td></tr><tr><td>Total</td><td>LLY</td><td>1,201,603</td><td>58.3%</td><td>57.5%</td><td>58.1%<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6a0a7667f9d52837",
        "value": 0.583,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>7.6%</td><td>7.7%</td><td>7.8%</td></tr><tr><td>Total</td><td>LLY</td><td>1,201,603</td><td>58.3%</td><td>57.5%</td><td>58.1%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>27.9",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "5d943285ddd44d88",
        "value": 0.575,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>7.7%</td><td>7.8%</td></tr><tr><td>Total</td><td>LLY</td><td>1,201,603</td><td>58.3%</td><td>57.5%</td><td>58.1%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>27.9%</td><td>28.5",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "b77d8605f71f9179",
        "value": 0.581,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>7.8%</td></tr><tr><td>Total</td><td>LLY</td><td>1,201,603</td><td>58.3%</td><td>57.5%</td><td>58.1%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>27.9%</td><td>28.5%</td><td>29.0",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "3ebe53a11178dbf4",
        "value": 0.27899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>58.3%</td><td>57.5%</td><td>58.1%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>27.9%</td><td>28.5%</td><td>29.0%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>13.6%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "3e053285b301d5a4",
        "value": 0.285,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>57.5%</td><td>58.1%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>27.9%</td><td>28.5%</td><td>29.0%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>13.6%</td><td>13.9%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0638ae856938cac8",
        "value": 0.29,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>58.1%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>27.9%</td><td>28.5%</td><td>29.0%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>13.6%</td><td>13.9%</td><td>12.8%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "eeb25fd169e4a4a4",
        "value": 0.136,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>27.9%</td><td>28.5%</td><td>29.0%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>13.6%</td><td>13.9%</td><td>12.8%</td></tr><tr><td>Victoza/Saxenda</td><td>NOVO</td><td>3,192</td><t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "0b9929e84e227469",
        "value": 0.139,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>28.5%</td><td>29.0%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>13.6%</td><td>13.9%</td><td>12.8%</td></tr><tr><td>Victoza/Saxenda</td><td>NOVO</td><td>3,192</td><td>0.2%</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c824bb4dc8d91bf2",
        "value": 0.128,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>29.0%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>13.6%</td><td>13.9%</td><td>12.8%</td></tr><tr><td>Victoza/Saxenda</td><td>NOVO</td><td>3,192</td><td>0.2%</td><td>0.1%</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "511b09412a632733",
        "value": 0.002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ".6%</td><td>13.9%</td><td>12.8%</td></tr><tr><td>Victoza/Saxenda</td><td>NOVO</td><td>3,192</td><td>0.2%</td><td>0.1%</td><td>0.1%</td></tr><tr><td>Total</td><td>NOVO</td><td>858,144</td><td>41.7%</td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d5a1f1e1a1eae579",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "3.9%</td><td>12.8%</td></tr><tr><td>Victoza/Saxenda</td><td>NOVO</td><td>3,192</td><td>0.2%</td><td>0.1%</td><td>0.1%</td></tr><tr><td>Total</td><td>NOVO</td><td>858,144</td><td>41.7%</td><td>42.5%</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c6e5d283cd46be71",
        "value": 0.001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "12.8%</td></tr><tr><td>Victoza/Saxenda</td><td>NOVO</td><td>3,192</td><td>0.2%</td><td>0.1%</td><td>0.1%</td></tr><tr><td>Total</td><td>NOVO</td><td>858,144</td><td>41.7%</td><td>42.5%</td><td>41.9%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "de1e3ffff10cce6d",
        "value": 0.41700000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td>0.2%</td><td>0.1%</td><td>0.1%</td></tr><tr><td>Total</td><td>NOVO</td><td>858,144</td><td>41.7%</td><td>42.5%</td><td>41.9%</td></tr></table> Market share - <table><tr><td rowspan=\"2\">Market",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a86ee5a4ee1263d6",
        "value": 0.425,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>0.1%</td><td>0.1%</td></tr><tr><td>Total</td><td>NOVO</td><td>858,144</td><td>41.7%</td><td>42.5%</td><td>41.9%</td></tr></table> Market share - <table><tr><td rowspan=\"2\">Market share - TRx j",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ca9f27fab073b6f3",
        "value": 0.419,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>0.1%</td></tr><tr><td>Total</td><td>NOVO</td><td>858,144</td><td>41.7%</td><td>42.5%</td><td>41.9%</td></tr></table> Market share - <table><tr><td rowspan=\"2\">Market share - TRx just sema/tirz<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7f81633db7da1fbb",
        "value": 0.332,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ks %</td><td>Past 12 weeks %</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>630,231</td><td>33.2%</td><td>33.2%</td><td>32.5%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>21.9",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d8590edf58713336",
        "value": 0.332,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ast 12 weeks %</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>630,231</td><td>33.2%</td><td>33.2%</td><td>32.5%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>21.9%</td><td>20.8",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "cfa7a898f8178c11",
        "value": 0.325,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>630,231</td><td>33.2%</td><td>33.2%</td><td>32.5%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>21.9%</td><td>20.8%</td><td>22.1",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "954afbdf4693dd02",
        "value": 0.21899999999999997,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>33.2%</td><td>33.2%</td><td>32.5%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>21.9%</td><td>20.8%</td><td>22.1%</td></tr><tr><td>M&amp;amp;Z</td><td>LLY</td><td>1,046,089</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "03b9da075a4b9878",
        "value": 0.20800000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>33.2%</td><td>32.5%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>21.9%</td><td>20.8%</td><td>22.1%</td></tr><tr><td>M&amp;amp;Z</td><td>LLY</td><td>1,046,089</td><td>55.0%</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "ffd594ff1463cccf",
        "value": 0.221,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>32.5%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>415,858</td><td>21.9%</td><td>20.8%</td><td>22.1%</td></tr><tr><td>M&amp;amp;Z</td><td>LLY</td><td>1,046,089</td><td>55.0%</td><td>54.0%</td><td",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "26d8224839fdb643",
        "value": 0.55,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "1.9%</td><td>20.8%</td><td>22.1%</td></tr><tr><td>M&amp;amp;Z</td><td>LLY</td><td>1,046,089</td><td>55.0%</td><td>54.0%</td><td>54.6%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>30.2",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "c5e2f5855d63535f",
        "value": 0.54,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "0.8%</td><td>22.1%</td></tr><tr><td>M&amp;amp;Z</td><td>LLY</td><td>1,046,089</td><td>55.0%</td><td>54.0%</td><td>54.6%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>30.2%</td><td>30.9",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fd73e3fe2a42a48f",
        "value": 0.546,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2.1%</td></tr><tr><td>M&amp;amp;Z</td><td>LLY</td><td>1,046,089</td><td>55.0%</td><td>54.0%</td><td>54.6%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>30.2%</td><td>30.9%</td><td>31.5",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7bee06773e8e5ffc",
        "value": 0.302,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>55.0%</td><td>54.0%</td><td>54.6%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>30.2%</td><td>30.9%</td><td>31.5%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>14.8%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "99f481f71af6f746",
        "value": 0.309,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>54.0%</td><td>54.6%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>30.2%</td><td>30.9%</td><td>31.5%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>14.8%</td><td>15.1%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "fb7af295b29568cc",
        "value": 0.315,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>54.6%</td></tr><tr><td>Ozempic</td><td>NOVO</td><td>574,408</td><td>30.2%</td><td>30.9%</td><td>31.5%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>14.8%</td><td>15.1%</td><td>13.9%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "9a383652f96dc971",
        "value": 0.14800000000000002,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>30.2%</td><td>30.9%</td><td>31.5%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>14.8%</td><td>15.1%</td><td>13.9%</td></tr><tr><td>O&amp;amp;W</td><td>NOVO</td><td>854,952</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "7f9df1be191ff64f",
        "value": 0.151,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>30.9%</td><td>31.5%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>14.8%</td><td>15.1%</td><td>13.9%</td></tr><tr><td>O&amp;amp;W</td><td>NOVO</td><td>854,952</td><td>45.0%</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "877de45dedd6ba82",
        "value": 0.139,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>31.5%</td></tr><tr><td>Wegovy</td><td>NOVO</td><td>280,544</td><td>14.8%</td><td>15.1%</td><td>13.9%</td></tr><tr><td>O&amp;amp;W</td><td>NOVO</td><td>854,952</td><td>45.0%</td><td>46.0%</td><td>",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "326629303fa36690",
        "value": 0.45,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "14.8%</td><td>15.1%</td><td>13.9%</td></tr><tr><td>O&amp;amp;W</td><td>NOVO</td><td>854,952</td><td>45.0%</td><td>46.0%</td><td>45.4%</td></tr></table> Source:IQVIA,Bernstein analysis EXHIBIT 15: Last",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "186938fa76a44e05",
        "value": 0.46,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "15.1%</td><td>13.9%</td></tr><tr><td>O&amp;amp;W</td><td>NOVO</td><td>854,952</td><td>45.0%</td><td>46.0%</td><td>45.4%</td></tr></table> Source:IQVIA,Bernstein analysis EXHIBIT 15: Last week's market",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "e8827617846d02c2",
        "value": 0.45399999999999996,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "13.9%</td></tr><tr><td>O&amp;amp;W</td><td>NOVO</td><td>854,952</td><td>45.0%</td><td>46.0%</td><td>45.4%</td></tr></table> Source:IQVIA,Bernstein analysis EXHIBIT 15: Last week's market share evoluti",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "1c9ea92630eb611a",
        "value": 0.304,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ks %</td><td>Past 12 weeks %</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>621,431</td><td>30.4%</td><td>30.4%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>414,376</td><td>20.2",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "9bcec13fc9d93a50",
        "value": 0.304,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ast 12 weeks %</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>621,431</td><td>30.4%</td><td>30.4%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>414,376</td><td>20.2%</td><td>19.4",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "a22ad8d63b681fe7",
        "value": 0.299,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td><td></td></tr><tr><td>Mounjaro</td><td>LLY</td><td>621,431</td><td>30.4%</td><td>30.4%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>414,376</td><td>20.2%</td><td>19.4%</td><td>20.3",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d19871b160cf951d",
        "value": 0.20199999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>30.4%</td><td>30.4%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>414,376</td><td>20.2%</td><td>19.4%</td><td>20.3%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>154,004</td><td>7.5",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "8395572262d7f77d",
        "value": 0.19399999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>30.4%</td><td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>414,376</td><td>20.2%</td><td>19.4%</td><td>20.3%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>154,004</td><td>7.5%</td><td>7.7%",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "806b23eef16fa3bd",
        "value": 0.203,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>29.9%</td></tr><tr><td>Zepbound</td><td>LLY</td><td>414,376</td><td>20.2%</td><td>19.4%</td><td>20.3%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>154,004</td><td>7.5%</td><td>7.7%</td><td>7.9%<",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "d8ad2c8e6935a52d",
        "value": 0.075,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>20.2%</td><td>19.4%</td><td>20.3%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>154,004</td><td>7.5%</td><td>7.7%</td><td>7.9%</td></tr><tr><td>Total</td><td>LLY</td><td>1,189,811</td><td>58.1%</t",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "6b4d4b3ba2d20734",
        "value": 0.077,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>19.4%</td><td>20.3%</td></tr><tr><td>Trulicity</td><td>LLY</td><td>154,004</td><td>7.5%</td><td>7.7%</td><td>7.9%</td></tr><tr><td>Total</td><td>LLY</td><td>1,189,811</td><td>58.1%</td><td>57.6%</",
        "provenance": {
          "page": 6
        }
      },
      {
        "num_id": "cbe090e495728d02",
        "value": 0.6729999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>Zepbound <br>vs PY (abs)</td><td>386,758</td><td>465,522</td><td>502,934</td><td>557,701</td><td>67.3%</td><td>69.4%</td><td>70.9%</td><td>62.4%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "92332b360459a52d",
        "value": 0.6940000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r>vs PY (abs)</td><td>386,758</td><td>465,522</td><td>502,934</td><td>557,701</td><td>67.3%</td><td>69.4%</td><td>70.9%</td><td>62.4%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "7ffe819717517d53",
        "value": 0.7090000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "/td><td>386,758</td><td>465,522</td><td>502,934</td><td>557,701</td><td>67.3%</td><td>69.4%</td><td>70.9%</td><td>62.4%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>1,433,535",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "b7c262c19cc66db0",
        "value": 0.624,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>465,522</td><td>502,934</td><td>557,701</td><td>67.3%</td><td>69.4%</td><td>70.9%</td><td>62.4%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>1,433,535</td><td>1,739",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ac9ae9fe7d05ef50",
        "value": 2.707,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>1,126,644</td><td>995,463</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>270.7%</td><td>273.6%</td><td>224.0%</td><td>178.5%</td></tr><tr><td>M+Z together <br>vs PY (abs)</t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "110c8285e6fd92f4",
        "value": 2.736,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>995,463</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>270.7%</td><td>273.6%</td><td>224.0%</td><td>178.5%</td></tr><tr><td>M+Z together <br>vs PY (abs)</td><td>1,710,853",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "3bb12369fe32ece6",
        "value": 2.24,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>270.7%</td><td>273.6%</td><td>224.0%</td><td>178.5%</td></tr><tr><td>M+Z together <br>vs PY (abs)</td><td>1,710,853</td><td>1,846,",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "9a912d9707dc451e",
        "value": 1.785,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">vs PY (%)</td><td></td><td></td><td></td><td></td><td>270.7%</td><td>273.6%</td><td>224.0%</td><td>178.5%</td></tr><tr><td>M+Z together <br>vs PY (abs)</td><td>1,710,853</td><td>1,846,841</td><td>1,9",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "48b990e77adc355c",
        "value": -0.034,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "d><td>96,312</td><td>100,399</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-3.4%</td><td>-8.2%</td><td>-13.2%</td><td>-13.9%</td></tr><tr><td>Ozempic <br>vs PY (abs)</td><td>2",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "9405db895f8291bf",
        "value": -0.08199999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>100,399</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-3.4%</td><td>-8.2%</td><td>-13.2%</td><td>-13.9%</td></tr><tr><td>Ozempic <br>vs PY (abs)</td><td>2,211,520</td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "69d4449a0bca6fef",
        "value": -0.132,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-3.4%</td><td>-8.2%</td><td>-13.2%</td><td>-13.9%</td></tr><tr><td>Ozempic <br>vs PY (abs)</td><td>2,211,520</td><td>2,331,556</",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "230400bc6b7b80a2",
        "value": -0.139,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-3.4%</td><td>-8.2%</td><td>-13.2%</td><td>-13.9%</td></tr><tr><td>Ozempic <br>vs PY (abs)</td><td>2,211,520</td><td>2,331,556</td><td>2,280,90",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "53badf7a7fed6af1",
        "value": 0.059000000000000004,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>Wegovy <br>vs PY (abs)</td><td>668,430</td><td>750,168</td><td>769,822</td><td>823,350</td><td>5.9%</td><td>2.1%</td><td>2.1%</td><td>-0.5%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ef2c5beb15e3ad0a",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "br>vs PY (abs)</td><td>668,430</td><td>750,168</td><td>769,822</td><td>823,350</td><td>5.9%</td><td>2.1%</td><td>2.1%</td><td>-0.5%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "deb32dfb9dbd9b61",
        "value": 0.021,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ")</td><td>668,430</td><td>750,168</td><td>769,822</td><td>823,350</td><td>5.9%</td><td>2.1%</td><td>2.1%</td><td>-0.5%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>858,206</t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "5a966c769bfcb9ec",
        "value": -0.005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ",430</td><td>750,168</td><td>769,822</td><td>823,350</td><td>5.9%</td><td>2.1%</td><td>2.1%</td><td>-0.5%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>858,206</td><td>924,222",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "85d8c8dfb26ee239",
        "value": 0.284,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "><td>265,186</td><td>302,784</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>28.4%</td><td>23.2%</td><td>34.4%</td><td>36.8%</td></tr><tr><td>O+W together <br>vs PY (abs)</td><t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "9c3bbd2ada82c40a",
        "value": 0.23199999999999998,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>302,784</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>28.4%</td><td>23.2%</td><td>34.4%</td><td>36.8%</td></tr><tr><td>O+W together <br>vs PY (abs)</td><td>2,879,950</t",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "d9a9a033c719d7e8",
        "value": 0.344,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>28.4%</td><td>23.2%</td><td>34.4%</td><td>36.8%</td></tr><tr><td>O+W together <br>vs PY (abs)</td><td>2,879,950</td><td>3,081,72",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "d877ee93622520c3",
        "value": 0.368,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>28.4%</td><td>23.2%</td><td>34.4%</td><td>36.8%</td></tr><tr><td>O+W together <br>vs PY (abs)</td><td>2,879,950</td><td>3,081,724</td><td>3,05",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "fba38f00b45057e0",
        "value": 0.111,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "axenda/Victoza) <br>vs PY (abs)</td><td>98,439</td><td>79,794</td><td>53,214</td><td>52,454</td><td>11.1%</td><td>7.3%</td><td>10.3%</td><td>9.3%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ffb0251be9b88e1f",
        "value": 0.073,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ") <br>vs PY (abs)</td><td>98,439</td><td>79,794</td><td>53,214</td><td>52,454</td><td>11.1%</td><td>7.3%</td><td>10.3%</td><td>9.3%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "79eef0c4ad596b0f",
        "value": 0.10300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "abs)</td><td>98,439</td><td>79,794</td><td>53,214</td><td>52,454</td><td>11.1%</td><td>7.3%</td><td>10.3%</td><td>9.3%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>10,814</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "394358da128ef69c",
        "value": 0.09300000000000001,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8,439</td><td>79,794</td><td>53,214</td><td>52,454</td><td>11.1%</td><td>7.3%</td><td>10.3%</td><td>9.3%</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>10,814</td><td>9,665</td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "ed3ff4bd6b85d6d8",
        "value": -0.89,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>44,314</td><td>41,597</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-89.0%</td><td>-87.9%</td><td>-83.3%</td><td>-79.3%</td></tr><tr><td>M+Z+O+W <br>vs PY (abs)</td><td",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "33d4246e5879cbf1",
        "value": -0.879,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td><td>41,597</td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-89.0%</td><td>-87.9%</td><td>-83.3%</td><td>-79.3%</td></tr><tr><td>M+Z+O+W <br>vs PY (abs)</td><td>4,590,803</td>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "cb1a96f19788f533",
        "value": -0.833,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "td></tr><tr><td>vs PY (%)</td><td></td><td></td><td></td><td></td><td>-89.0%</td><td>-87.9%</td><td>-83.3%</td><td>-79.3%</td></tr><tr><td>M+Z+O+W <br>vs PY (abs)</td><td>4,590,803</td><td>4,928,565</",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "026c81065d28d680",
        "value": -0.7929999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">vs PY (%)</td><td></td><td></td><td></td><td></td><td>-89.0%</td><td>-87.9%</td><td>-83.3%</td><td>-79.3%</td></tr><tr><td>M+Z+O+W <br>vs PY (abs)</td><td>4,590,803</td><td>4,928,565</td><td>4,960,20",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1ae61916adf07502",
        "value": 0.49200000000000005,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "8</td><td>2,436,954</td><td>2,238,916</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>49.2%</td><td>49.8%</td><td>49.1%</td><td>42.9%</td></tr></table> Source:IQVIA,Bernstein analysis<｜e",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "f55cdb381c778fa8",
        "value": 0.498,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "6,954</td><td>2,238,916</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>49.2%</td><td>49.8%</td><td>49.1%</td><td>42.9%</td></tr></table> Source:IQVIA,Bernstein analysis<｜end▁of▁sentence",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "31b6dd780cee5471",
        "value": 0.491,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "2,238,916</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>49.2%</td><td>49.8%</td><td>49.1%</td><td>42.9%</td></tr></table> Source:IQVIA,Bernstein analysis<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1ecf9ef48711bddf",
        "value": 0.429,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "</tr><tr><td></td><td></td><td></td><td></td><td></td><td>49.2%</td><td>49.8%</td><td>49.1%</td><td>42.9%</td></tr></table> Source:IQVIA,Bernstein analysis<｜end▁of▁sentence｜>",
        "provenance": {
          "page": 8
        }
      },
      {
        "num_id": "1ef365f96dd394b4",
        "value": 0.52,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ns strong (W/E 18th April)- 21 Apr 2025 - GLP1 tracker: The story repeats - LLY keeps taking share (52%), growing faster than supply guidance & faster than NOVO (W/E 11th April)- 14 Apr 2025 - GLP1 tr",
        "provenance": {
          "page": 10
        }
      },
      {
        "num_id": "fde63cea87474304",
        "value": 0.5,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "h] - 10 Mar 2025 - GLP1 Tracker: Lilly continues to outgrow Novo with market share now rounding to 50% [W/E 28th Feb] - 3 Mar 2025 - GLP1 Tracker: Lilly continues to outgrow Novo with market share str",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "f9ddbcb2638aaeee",
        "value": 0.491,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ar 2025 - GLP1 Tracker: Lilly continues to outgrow Novo with market share stretching towards equal (49.1%) [W/E 21st Feb] - 25 Feb 2025 - GLP1 tracker: Zepbound price-drop announced, uptick with Lilly",
        "provenance": {
          "page": 11
        }
      },
      {
        "num_id": "dcc2efe8eae1fd3b",
        "value": 0.079,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "tes. ## VALUATION METHODOLOGY ## Eli Lilly & Co We arrive at our valuation using a blend of DCF (7.9% WACC, 6% FCFF CAGR to '43 and 3% TV GR) and multiples approach - with valuation more heavily weigh",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "69a7d54111873a0a",
        "value": 0.06,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "LUATION METHODOLOGY ## Eli Lilly & Co We arrive at our valuation using a blend of DCF (7.9% WACC, 6% FCFF CAGR to '43 and 3% TV GR) and multiples approach - with valuation more heavily weighted toward",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "df8d8fbdd22aefb2",
        "value": 0.03,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Eli Lilly & Co We arrive at our valuation using a blend of DCF (7.9% WACC, 6% FCFF CAGR to '43 and 3% TV GR) and multiples approach - with valuation more heavily weighted toward the DCF. Our \\(\\) 1100",
        "provenance": {
          "page": 12
        }
      },
      {
        "num_id": "ac36c1f18e0be4a5",
        "value": 0.5127,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "Percent</td><td>Count*</td><td>Percent*</td></tr><tr><td>Outperform</td><td>BUY</td><td>585</td><td>51.27%</td><td>110</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td rowspan=",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "357859d971bc1565",
        "value": 0.188,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "<td>Percent*</td></tr><tr><td>Outperform</td><td>BUY</td><td>585</td><td>51.27%</td><td>110</td><td>18.80%</td></tr><tr><td>Market-Perform (Bernstein Brand)</td><td rowspan=\"2\">HOLD</td><td rowspan=\"2",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "d77f55f3d2923156",
        "value": 0.3567,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "rket-Perform (Bernstein Brand)</td><td rowspan=\"2\">HOLD</td><td rowspan=\"2\">407</td><td rowspan=\"2\">35.67%</td><td rowspan=\"2\">76</td><td rowspan=\"2\">18.67%</td></tr><tr><td>Neutral (Autonomous Brand)",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "c27a744cfd34a562",
        "value": 0.1867,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": ">HOLD</td><td rowspan=\"2\">407</td><td rowspan=\"2\">35.67%</td><td rowspan=\"2\">76</td><td rowspan=\"2\">18.67%</td></tr><tr><td>Neutral (Autonomous Brand)</td></tr><tr><td>Underperform</td><td>SELL</td><t",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "60c60b68d5ba4f32",
        "value": 0.1306,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "r><tr><td>Neutral (Autonomous Brand)</td></tr><tr><td>Underperform</td><td>SELL</td><td>149</td><td>13.06%</td><td>20</td><td>13.42%</td></tr></table> \\* These figures represent the number and percent",
        "provenance": {
          "page": 13
        }
      },
      {
        "num_id": "4f485bead54b20a6",
        "value": 0.13419999999999999,
        "unit": "percentage",
        "metric_type": "percentage",
        "context": "ous Brand)</td></tr><tr><td>Underperform</td><td>SELL</td><td>149</td><td>13.06%</td><td>20</td><td>13.42%</td></tr></table> \\* These figures represent the number and percentage of companies in each c",
        "provenance": {
          "page": 13
        }
      }
    ],
    "claims": [],
    "relations": [],
    "extraction_summary": {
      "figures_count": 16,
      "tables_count": 0,
      "numerical_data_count": 148,
      "passages_count": 147,
      "entities_count": 20
    }
  }
}